 
 Cover Page for Protocol  
Study ID: [REMOVED]  
Official title of study:  A Phase 2 Clinical Trial of Entinostat in  
Combination with Nivolumab for Patients with 
Previously Treated Unresectable or Metastatic  
Cholangiocarcinoma and Pancreatic  
Adenocarcinoma  
Document Date:  May 21, 2020  
  
 
   
 
  
Version:   Original/ Version 1/July 5, 2017  
Original/ Version 1.1/July 27, 2017  
Original/ Version 1.2/July 28, 2017  
Original/ Version 1.3/August 11, 2017  
Original/ Version 1.4/October 10, 2017  
Amendment 1/ Version 2.0/March 19, 2018  
Amendment 2/ Version 3.0/April 25, 2019  
Amendment 3/Version 4.0/October 10, 2019  
Amendment 3/Version 5.0/May 21, 2020  
  
  
  
  
    
    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
  
STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
2  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
J1798/Version 5.0/May 21, [ADDRESS_376885]  Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events   
CTLA -4  Cytotoxic T -lymphocyte -associated antigen -4  
DKA  Diabetic ketoacidosis  
DNA  Deoxyribonucleic acid  
  
  
STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
3  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
EC  Ethics Committee  
ECG  Electrocardiogram  
ECI   Events of clinical interest  
ECOG  Eastern Cooperative Oncology Group  
 
eCRF  Electronic case report form  
EDC  Electronic data capture  
EMA  European Medicines Agency  
EOT  End of Treatment  
FDG  18F-deoxyglucose  
FGFR  Fibroblast Growth Factor Receptor  
FoxP3  Forkhead box P3  
G-CSF  Granulocyte -colony stimulating factor  
GI  Gastrointestinal  
GM-CSF  Granulocyte macrophage -colony stimulating factor  
G-MDSCs  Granulocytic myeloid -derived suppressor cells  
HDAC  Histone deacetylase  
HIV  Human immunodeficiency virus  
IB  Investigator’s Brochure  
ICH  International Conference on Harmonisation  
IFN-
  Interferon -gamma  
Ig  Immunoglobulin  
IND  Investigational New Drug Application  
  
  
STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
4  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
INR  International normalized ratio  
irAE  Immune -related adverse events  
IRB  Institutional Review Board  
irRECIST  Immune -related Response Evaluation Criteria in Solid Tumors  
IV  Intravenous(ly)  
LDH  Lactic dehydrogenase  
 
mAb  Monoclonal antibody  
MDSC  Myeloid -derived suppressor cells  
MRI  Magnetic resonance imaging  
MTD  Maximum tolerated dose  
NCI  National Cancer Institute  
NSCLC  Non-small cell lung cancer  
NYHA  [LOCATION_001] Heart Association  
ORR  Overall response rate  
OS  Overall survival  
PBMCs  Peripheral Blood Mononuclear Cells  
PD  Progressive disease  
PDAC  Pancreatic Ductal Adenocarcinoma  
PD-1  Programmed death receptor -1  
PD-L1  Programmed death ligand -1  
PD-L2  Programmed death ligand -2  
PET  Positron emission tomography  
  
  
STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
5  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
PFS  Progression -free survival  
PK  Pharmacokinetic  
PO  By [CONTACT_308047] (count)  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE  Serious adverse event  
 
SC  Subcutaneous(ly)  
SD    
  Stable Disease  
SOC  System organ class  
T1DM  Type [ADDRESS_376886]  Upper limit of normal  
WBC  White blood cell (count)  
  
  
STUDY GLOSSARY  
Abbreviation/Acronym  Definition  
6  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 WOCBP  
  Women of child -bearing potential  
    
  
  
  
  
8  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
STUDY GLOSSARY .............................................................................................................. ...... 
2 SCHEMA 
................................................................................................................... .................... 6 1. 
OBJECTIVES .................................................................................................................. ....... 10   
1.1 Primary Objective ....................................................................... ................................ 10   
1.2 Secondary Objectives.................................................................................................. 10   
1.3 Exploratory Objectives ................................................................. .............................. 10   
1.4 Primary Endpoint ........................................................................................................  11  
1.5 Secondary Endpoints ................................................................... ............................... 11   
1.6 Exploratory Endpoints ................................................................................................ 11   
2. BACKGROUND AND RATIONAL .................................................................. ................... 
12  
2.1 Disease(s) Background ............................................................................................... 12   
2.2 Immunotherapy ........................................................................................ ................... 13   
2.3 Epi[INVESTIGATOR_307988] a Target for New Therapy .................................................... 15   
2.4 Immunotherapy as an Anticancer Strategy in PDAC and CCA ................................. 18   
2.5 Investigational Agents ................................................................................................ 2 0  
2.6 Entinostat in Combination with PD -1 Checkpoint Inhibition: Rational of the Study 26   
3. PATIENT SELECTION .................. ...................................................................................... 33   
3.1 Eligibility Criteria .................................................................................................... ... 33   
3.2 Exclusion Criteria ......... .............................................................................................. 34   
3.3 Inclusion of Women and Minorities ........................................................................... 37   
4. TREATMENT PLAN ..................... ........................................................................................ 
38  
4.1 Agents Administration ................................................................................................ 38   
4.2 Overall Study Design ........... ....................................................................................... 38   
  
  
  
  
9  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
4.3 Definition of Unacceptable Toxicities ........................................................................ 39   
4.4 Study Drugs ............................................................................................................. ... 40   
4.5 Supportive Care Guidelines and General Concomitant Medication ........................... 41   
4.6 Definition of an Over dose for this Protocol ................................................................ 45   
4.7 WOCBP, Contraception, Use in Pregnancy, Use in Nursing ..................................... 45   
4.8 Duration of Treatment and Criteria for Removal from Treatme nt ............................. 48   
4.9 Treatment Beyond Progression ................................................................................... 49   
4.10 Duration of Follow Up ....................................................................... ....................... 50   
5. DOSING DELAYS/DOSE MODIFICATIONS ................................................................... 
51  
5.1 Dose Criteria ......................................................................................................... ...... 51  
6. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS ............................. 
62 
6.1 Study Drugs ............................................................................................................. ... 62   
6.2 Adverse Events Definitio n .......................................................................................... 63   
6.3 Reporting Procedures for All Adverse Events ............................................................ 65   
6.4 Serious Adverse Event Reporting Procedures  ............................................................ 67   
6.5 Pregnancy and Lactation Reporting Procedures ......................................................... 68   
6.6 Reporting of Overdose to the Sponsor ...................................... .................................. 69   
6.7 Follow -Up of Adverse Events .................................................................................... 69  
  6.8 Reconciliation of SAEs………………………………………………………………69  
6.9 Safety Reporting to Health Authoriti es, Ethics Committees/Institutional Review  
Boards and Investigators ................................................................................................... 70  
6.10 Food and Drug Administration (FDA) Reporting .................................................... 70   
6.11 Protocol Deviations Due to an Emergency or Adverse Event .................................. 71   
6.12 Safety Monitoring ......................... ............................................................................ 71   
  
  
  
  
10  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
7. PHARMACEUTICAL INFORMATION ............................................................................. 
72  
7.1 Entinostat (NSC #706995) .................................. ........................................................ 72   
7.2 Nivolumab (NSC #748726) ........................................................................................ [ADDRESS_376887] – Solid Tumors (RECIST 1.1) ........................................................ 76   
8.2 Definitions.................................................................................... ............................... 77   
8.3 Response Criteria ....................................................................................................... . 80  
8.4 Safety/tolerability ................................................................. ....................................... 
84  
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES .......................................... 
85  
9.1 Overview ......................................................................................................... ............ 
85  
9.2 Collection of Specimens ............................................................................................. 85   
9.3 Methods...................................................................................................... ................. 87   
10. STUDY CALENDAR .......................................................................................................... . 89 
11. DATA REPORTING / REGULATORY REQUIREMENTS .......................................... 
[ADDRESS_376888] Anonymity ........................................................... 95   
11.3 Protocol Compliance .... ............................................................................................. 95   
11.4 Safety meetings ........................................................................................................ . 96 
11.5 Monitoring ............ .................................................................................................... 96  
12. STATISTICAL CONSIDERATIONS ................................................................................ 
97  
12.1 Overall Study Design ................................................................................................ 97   
  
  
  
  
11  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
12.2 Sample Size and Accrual Rate .................................................................................. 97   
12.3 Stu dy Endpoints Analyses ........................................................................................ 98   
13. REFERENCES .............................................................................................................. ...... 
101 14. A PPENDICES 
..................................................................................................................... 111   
Appendix A: Eastern Cooperative Oncology Group Performance Status Scale, with  
Equivalent Karnofsky Performance Status Scor es ......................................................... 111   
Appendix B:  Patient Drug Information Handout and Wallet Card ................................ 112   
Appendix C:  Entinostat Drug Diary .............................................................................. 114   
Appendix D: Management Algorithms for Nivolumab -Related Adverse Events ......... 115   
Appendix E: Concomitant Medications to be Avoided .................................................. 123   
Appendix F: Serious Adverse Event Reporting Form .................................................... 124   
Appendix G: Nivolumab Product Information Table ............................................. ........ 126   
  
  
  
  
  
  
  
    
1. OBJECTIVES  
  
1.1 Primary Objective  
  
1.1.1  To determine the objective response rate (ORR) of entinostat plus nivolumab in patients 
with unresectable or metastatic cholangiocarcinoma and unresectable or metastatic 
pancreatic adenocarcinoma, who have progressed after one more two lines of prior 
thera py.  
  
  
  
  
12  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
1.2 Secondary Objectives  
  
1.2.1 To assess the safety and tolerability of entinostat plus nivolumab in patients with 
unresectable or metastatic cholangiocarcinoma and unresectable or metastatic 
pancreatic adenocarcinoma.   
   
1.2.2 To assess the pr ogression free survival (PFS) status of patients with unresectable or 
metastatic cholangiocarcinoma and unresectable or metastatic pancreatic 
adenocarcinoma treated with entinostat plus nivolumab at 6, 12 and 24 months.    
  
1.2.3 To determine the overall s urvival (OS) status of subjects with unresectable or metastatic 
cholangiocarcinoma and unresectable or metastatic pancreatic adenocarcinoma treated 
with entinostat plus nivolumab.   
  
1.2.4  To determine the overall survival (OS) status of subjects with unresectable or metastatic 
cholangiocarcinoma and unresectable or metastatic pancreatic adenocarcinoma treated 
with entinostat plus nivolumab at 6 months, at 1, 2 and 3 years.   
  
1.2.5 To asses s the duration of response among subjects who demonstrate an objective 
response to treatment with entinostat in combination with nivolumab.   
  
1.3 Exploratory Objectives  
  
1.3.1 To measure the baseline levels of  immune markers including CD8+ T effector cells and 
CD4+FoxP3+ T regulatory cells, PD -L1 expression and tumor infiltrating lymphocytes 
(TILs), major histocompatibility complex (MHC) class I and II expression, and natural 
killer (NK) cell receptors and ligands expression and correlate these variables with 
treatment response and toxicity.  
  
1.3.2 To characterize changes in the immune markers described above after treatment  
  
  
  
  
  
13  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
1.3.3 To identify gene expression changes in mali gnant tissue after therapy, and complete gene 
set analysis to elucidate affected pathways  
  
1.3.4  To measure changes in circulating immune suppressor cells (myeloid derived 
suppressor cells (MDSC), Treg) in peripheral blood by [CONTACT_308048].  
  
1.3.5 To assess the baseline characteristics of the subjects enrolled and to correlate these 
molecular and clinicopathologic criteria with treatment response and toxicity.   
  
1.4 Primary Endpoint  
  
1.4.1  ORR, defined as the proportion of patients achieving a complete response (CR) or partial 
response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 
at any time during the study, of entinostat in combination with nivolumab in pati ents 
with unresectable or metastatic cholangiocarcinoma and unresectable or metastatic 
pancreatic adenocarcinoma.  
  
1.5 Secondary Endpoints     
  
1.5.1 Adverse events as graded by [CONTACT_308049].  
  
1.5.2 Progression Free Survival (PFS) status a t 6, 12 and 24 months.  
  
1.5.3 Duration of Response (DOR).  
  
1.5.4 Overall Survival (OS).  
  
1.5.5 OS at 6 months, at 1, 2 and 3 years  
  
1.6 Exploratory Endpoints  
  
  
  
  
  
14  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
1.6.1 Changes in immune -related biomarkers (e.g., expression of checkpoint receptors 
(PD1/PD -L1), the number of MDSCs, inflammatory T cell signature, in tumor biopsies 
and peripheral blood pre - and post -therapy and their correlation with response to 
therapy.  
1.6.2 Gene expression changes in circulating DNA and malignant tissue after therapy, and 
complete gene set analysis to elucidate affected pathways  
1.6.3 Changes in circulating immune suppressor cells (MDSC, Treg) in peripheral blood by 
[CONTACT_308050]   
  
  
  
  
  
  
2. BACKGROUND AND RATIONAL  
  
2.1 Disease(s) Background  
  
2.1.1 Pancreatic Adenocarcinoma  
  
Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies 
with a 5 -year survival rate of <7%, due to growing incidence, late diagnosis and insufficient 
treatment options [1]. Although intensified cytostatic combinations, p articularly gemcitabine plus 
nabpaclitaxel and the folinic acid, fluorouracil, irinotecan, oxaliplatin  (FOLFIRINOX) protocol, 
provide some improvement in efficacy and survival compared with gemcitabine alone, a 
breakthrough in the treatment of metastatic pancreatic cancer remains out of sight [2, 3]. The 
nanoliposomal formulation of irinotecan, MM -398, in combinations with 5FU resulted in a two 
month improvement in median survival compared to 5FU and leucovorin [4]. Similarly the 
combination of weekly 5FU,  leucovorin and oxaliplatin after gemcitabine failure resulted in a 
median overall survival of 5.9 months versus 3.3 months for weekly 5FU and leucovorin in the 
CONKO -003 trial [5]. However, a more recent trial showed no difference in outcome with 5FU 
versus 5FU and oxaliplatin in the same setting [6].  
  
  
  
  
  
15  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Based on this, there is an urgent need for the development of more effective therapi[INVESTIGATOR_307989]. One of the emerging interests in PDAC therapy is 
immunotherapy because th ese tumors generally escape immune surveillance through various 
mechanisms [7]. Unfortunately to date, monotherapy with immune checkpoint blockade that have 
being investigated, resulted ineffective in PDAC.   
  
Given the great promise of immune -based thera pi[INVESTIGATOR_307990], there is reason to hope 
that modulating the tumor microenvironment could also augment tumor control in this context (see 
Sections 2.4  and 2.5).  
  
 2.1.2 Cholangiocarcinoma  
  
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most 
common primary hepatic malignancy. It is classified into intrahepatic (iCCA) and extrahepatic 
cholangiocarcinoma (eCCA) subtypes, the latter often further divided in perihilar (pCCA), and 
distal (dCCA).  The overall pro gnosis of CCA is dismal, with surgery as the only option for cure, 
but given the propensity for early metastasis and high recurrence, 5 -year OS ranges from 14 to 40 
% after surgical resection [8, 9]. In the setting of metastatic disease we still have limit ed treatment 
options, and so far the combination of gemcitabine and cisplatin has been established as the 
standard of care first line systemic therapy option with a median survival of 11 months [10]. There 
are no established second line treatment options [ 9, 11].   
  
This huge unmet clinical need supports exploring novel therapi[INVESTIGATOR_014]. Our understanding of the 
molecular tumor biology of CCA has been increased in the last years. For instance, Isocitrate 
Dehydrogenase 1 or 2 ( IDH1/2 ), BAP1  mutations and FGFR  fusions are more likely to occur in 
iCCA while KRAS , p53, and SMAD4  mutations are more common in eCCA. The mutational 
aberrations landscape vary with etiology, ethnicity and association with chronic liver disease too 
[9, 11]. Several clinical trials have demon strated the potential role of monoclonal antibodies in 
improving patient outcomes via the targeting of interactions between immune regulatory 
checkpoint molecules and their ligands.  
  
  
  
  
  
16  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Despi[INVESTIGATOR_307991], it remains unknown whether this adaptive immune 
resistance pathway is relevant among patients with CCA and whether similar novel therapi[INVESTIGATOR_307992].  
Several data suggest that the Programmed Death -1 (PD -1) and its ligands (Program med 
DeathLigand 1, PD -L1) pathway may be actively suppressing the host immune response in patients 
with ICC and can be a potential target for future therapi[INVESTIGATOR_014], providing a rationale for clinical trials 
to assess the efficacy and safety of anti -PD-1/PD -L1 therapi[INVESTIGATOR_307993] (see 
Section  
2.4 and 2.5).  
  
2.[ADDRESS_376889] it. Immunomodulation is based on the finding that stimulation of   
T‑cell function with antibodies that block or activate regulatory receptor s, can cause the regression 
of some tumors. The generation of immunological memory is another unique feature of immune 
modulation as an effective cancer therapy [12].    
  
As far, antitumor immunotherapy has broad potential and could be used to treat many different 
types of advanced stage cancers owing to the durable and robust responses it elicits across a diverse 
spectrum of malignancies. Recent evidence highlights the pi[INVESTIGATOR_307994] -cytotoxic T -cell 
lymphocyte -associated protein 4 (CTLA -4) rece ptor, and PD -1 T cell co -receptor and its ligands 
B7-H1/PD -L1 and B7 -DC/PD -L2 in maintaining an immunosuppressive tumor microenvironment 
(TME), as part of the so called immune checkpoints family [13 -15]. Immune -cell-targeted 
monoclonal antibodies (mAbs) th erapy against these checkpoints inhibitors has emerged as 
particularly effective, having the potential to enhance and sustain endogenous immunity against 
tumor antigens and establishing durable tumor control.   
Clinical trials with anti –CTLA -4, anti –PD-1, and anti –PD-L1 mAbs, showed remarkable 
therapeutic responses [16 -19], underscoring the idea that disruption of immune checkpoints can be 
therapeutically useful.   
  
  
  
  
  
17  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Since, immunomodulatory mAbs target immune cel ls rather than cancer cells, we expect they are 
not necessarily specific to any cancer type.  However, despi[INVESTIGATOR_307995], 
the successes to date do not fully capture the promise of immunotherapy: the objective responses 
are observ ed in a minority of the treated patients and tumor types, and the reasons why certain 
tumors respond and others do not are not fully understood [20].   
  
It has been hypothesized that some tumor types with a more “immunogenic profile” that naturally 
attrac t T cell infiltration, are more likely to respond to checkpoint blockade. Evidence for this 
hypothesis is supported by [CONTACT_308051] a subset of lung adenocarcinomas with 
higher levels of somatic mutations had increased levels of inflammation -related gene expression 
and immune -checkpoint effector molecules, including PD‑L1 and the evidence that the prevalence 
of neoantigens can be predictive of the response to checkpoint blockade with PD‑1‑targeted 
therapy in patients with non -small cell lung c ancer (NSCLC), and with CTLA‑4‑targeted therapy 
in those with melanoma [21, 22].   
  
Conversely, tumors with low neoantigen -presenting capacity, such as those that have a reduced 
number of potentially immunogenic somatic mutations or that do not present ne oantigens through 
downregulated antigen processing, presentation or HLA expression might be overlooked by 
[CONTACT_4727] T cells [12, 23]. In this situation, antigen presentation and tumor -infiltrating 
lymphocytes (TILs) burden will likely be low, and immune -modulating mAbs alone would be 
less likely to generate a robust antitumor response, unless it is administered in the proper 
therapeutic context.  
  
For instance, CCA and PDAC, has generally been considered a nonimmunogenic malignancy, 
insofar as tumor -infiltrating effector T lymphocytes do not represent a histopathologic hallmark of 
this disease. To date, studies of anti –CTLA -4 and anti –PD-[ADDRESS_376890] failed to demonstrate any 
objective responses in this setting, unless in the small fraction (about 3% of PDA C) of patients 
with hypermutated tumors and microsatellite instability [24].  
  
Strategies to sensitize these tumors to checkpoint inhibition are warranted and the epi[INVESTIGATOR_307996] a very important role in this framework.    
  
  
  
  
  
18  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
  
2.[ADDRESS_376891] be heritable itself, and also highly 
adapta ble. The non -genetic determinants that precisely control the patterns of gene expression in 
cells are commonly referred to as epi[INVESTIGATOR_307997] [25].   
Cancer cells represent a complex interplay between genetic and epi[INVESTIGATOR_307998], from 
beginning to end, drive the evolution of each patient’s malignancy. It has been demonstrated that 
virtually all tumors harbour mutations in genes that control the epi[INVESTIGATOR_307999] [26].   
  
Four major mechanisms are involved in the epi[INVESTIGATOR_308000]: 
covalent modification of DNA; covalent modification of histones; non -protein -coding RNAs  
(microRNAs –miRNAs -) and long non -coding RNAs (lncRNAs). Currently, the most studied and 
recognized cancer -specific epi[INVESTIGATOR_308001] [27 -29].  
  
Cancer -specific hypermethylation of hundreds of genes per tumor, typi[INVESTIGATOR_308002], dinucleotides containing cytosine and guanine (CpG) -enriched DNA sequences 
(so called the  CpG islands) that reside in and around proximal gene promoters [27]. This 
hypermethylation can be associated with decreased gene expression, thus providing an alternative 
way to silence well known tumor suppressor genes. This mechanism is nowadays recogni zed as 
an early and central event in carcinogenesis [28, 29].   
  
Additionally, cancer -specific epi[INVESTIGATOR_308003], including histone deacetylation as well as decreases in methylation at lysine 4 of histon e 
3 (H3K4an), that is known to be an active mark of gene transcription at promoters of DNA 
hypermethylated genes [30, 31]. These changes led to an important change in chromatin 
conformation, resulting in a close configuration and, indeed, in a decreased ge ne expression, even 
in the absence of DNA methylation.   
  
  
  
  
  
19  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
These epi[INVESTIGATOR_308004], including PDAC and CCA. A number of elegantly conducted translational 
studies have provided significant evidence that dysregulation of chrom atin organization strongly 
contributes to the aggressive behavior of PDAC and CCA, by [CONTACT_308052]. In addition, whole genomic sequencing revealed pathogenic mutations and 
structural variants in several epi[INVESTIGATOR_41353] c regulator genes in these cancer types [32, 33].    
  
Consequently, several clinical trials have been initiated to determine the safety and efficiency of 
epi[INVESTIGATOR_308005].DNA methyltransferase and HDAC inhibitors 
have been in  clinical development as single agents for a number of years. Three HDAC inhibitors, 
vorinostat (Zolinza), romidepsin (Istodax) and panobinostat (Farydak) have reached approval by 
[CONTACT_3133] (FDA) or by [CONTACT_308053] y (EMA) for 
the treatment of cutaneous T -cell lymphoma (vorinostat and romidepsin), peripheral T -cell 
lymphoma (romidepsin) and multiple myeloma (vorinostat and panobinostat). The presumptive 
mechanism of action of these drugs is the activation of tumor su ppressor genes or 
immunityassociated genes silenced in tumor cells [34, 35].    
  
Study by [CONTACT_308054]: the induction of a 
substantial reduction of the number of tumor -infiltrating myeloid derived suppressor ce lls  
(MDSCs) especially when combined with immune checkpoint blockade, as discussed below [36].     
  
2.3.1 HDAC Inhibitors  
  
Histone acetylation is controlled by a balance in activity between histone acetyltransferase (HAT) 
and HDAC. HDAC inhibitors are c ritically important in the regulation of gene expression and in 
the field of target -specific anticancer drug development [34, 35, 37, 38]. The HDACs exert their 
targeted action during post -translational acetylation of core nucleosomal histones, which affec ts 
chromatin structure, thereby [CONTACT_308055].   
  
DNA that is wrapped around condensed, non -acetylated histones is transcriptionally inactive, 
whereas acetylation of N -terminal histone lysine residues exposes DNA to important transcription 
factors that promote transcriptional activity.  The action of HDACs on nucleosomal histones leads 
  
  
  
  
20  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
to tight coiling of chromatin and silencing of expression of various genes, including those 
implicated in the regulation of cell survival, proliferation, differ entiation, and apoptosis [34, 35].   
  
The effects of HDACs are not limited to histone deacetylation. HDACs also act as members of a 
protein complex to recruit transcription factors to the promoter region of genes, including those of 
tumor suppressors, and  they affect the acetylation status of specific cell cycle regulatory proteins. 
Because aberrant HDAC activity has been implicated in a variety of cancers, development of 
HDAC inhibitors is a rational approach to the design of targeted anticancer therapeut ics [35]. 
Several HDAC inhibitors have been studied in phase [ADDRESS_376892] in 
vivo [28, 29, 35].   
  
Recent preclinical investigations highlight the Tregs -targeting and immune -promoting effect of a 
class I specific HDAC inhibitor, entinostat, in combination  with either IL -2 in a murine renal cell 
carcinoma (RENCA) model or a surviving based vaccine therapy (SurVaxM) in a castration 
resistant prostate cancer (CR Myc -CaP) model [39].  
  
[IP_ADDRESS] Rationale for use HDAC inhibitors in cholangiocarcinoma   
  
Expression of HDACs was studied in CCA cell lines (M213, M214 and KKU -100) and an 
immortal cholangiocyte (MMNK1) by [CONTACT_31576] -quantitative reverse transcription -PCR, demonstrating 
that HDACs were expressed in all studied cell types. HDAC inhibitors in this stud y inhibited cell 
proliferation in a dose -dependent manner. Interestingly, KKU -100 which was less sensitive to 
classical chemotherapeutic 5 -FU was highly sensitive to HDAC inhibitors. Simultaneous 
combination of subtoxic doses of HDAC inhibitors and 5 -FU si gnificantly inhibited cell 
proliferation in CCA cell lines compared to single agent treatment, showing a synergistic antitumor 
potential of simultaneous combination of HDAC inhibitors and cytotoxic chemotherapy [40].   
  
  
  
  
  
21  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Another study investigate the antip roliferative effect of the HDAC inhibitor, entinostat, on CCA 
cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or 
the novel anticancer agents sorafenib or bortezomib, using two human bile duct adenocarcinoma 
cell lines (EGI -1 and TFK -1). They demonstrated that entinostat treatment potently inhibited the 
proliferation of EGI -[ADDRESS_376893]. 
Entinostat -induced apoptosis was characterized by [CONTACT_308056] -3, up-regulation of Bax 
and down -regulation of Bcl -2. Cell cycle was predominantly arrested at the G1/S checkpoint, 
which was associated with induction of the cyclin -dependent kinase inhibitor p21Waf/CIP1.   
Furthermore, additive anti -neoplastic effects wer e observed when entinostat treatment was 
combined with gemcitabine or doxorubicin, while combination with the multi -kinase inhibitor 
sorafenib or the proteasome inhibitor bortezomib resulted in overadditive anti -neoplastic effects 
[41].   
 [IP_ADDRESS] Rational for Use HDAC Inhibitors in PDAC  
  
Whilst HDAC inhibitors have been investigated in numerous clinical trials with patients suffering 
from hematological cancers and other solid tumors, there are only few studies so far that tested 
them in PDAC patients.  
  
In two phase I studies testing the safety and activity of entinostat given alone and in combination 
with 13 -cis-retinoic acid (13 -cR), one PDAC patient either was enrolled, achieving stable disease 
in the first setting, while progressive disease was noted after combined treatment [42].   
In other phase I studies investigating the safety of oral treatment with mocetinostat and dacinostat 
respectively, PDAC patients had no objective tumor response.   
  
In a phase I study tested the safety of combined treatmen t with belinostat plus carboplatin and/or 
paclitaxel, one PDAC patient of three showed partial remission after receiving belinostat and 
carboplatin. The same result was obtained in another phase I study investigating the combination 
of valproic acid with e pi[INVESTIGATOR_14962].   
  
A phase I study with 21 advanced PDAC patients investigated the maximally tolerated doses of 
concurrent vorinostat and capecitabine with radiation in neoadjuvant chemoradiation of 
  
  
  
  
22  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
unresectable and borderline patients. The authors claimed pot ential activity of vorinostat in 
neoadjuvant chemoradiation to improve the intervention option in borderline patients.  
    
The combinations of vorinostat with proteasome inhibitors showed some potential for the 
treatment of certain advanced solid tumors, thus it has investigating in PDAC. So far, all the study 
revealed no favorable responses in PDAC patients [43, 44].  
  
Another phase I trial tested oral panobinostat combined with gemcitabine in  advanced solid 
tumor patients, including 3 PDAC patients, of  which 1 had stable disease under treatment [45]. 
Likewise, in a phase I study combining 9 PDAC -patients were treated, and five of them obtain 
stable disease [46].   
A phase II study explored the activity of tacedinaline alone in 17 PDAC patients albeit well 
tolerated, no significant antitumoral activity was noted either in monotherapy or in combined 
treatment with gemcitabine [47].  
  
2.[ADDRESS_376894] shown limited benefit to date in solid tumors that are not 
traditionally felt to be immunogenic (e.g., CCA and PDAC). This may relate to the presence of 
immunosuppressive factors which may be overcome through epi[INVESTIGATOR_195434] [48]. Indeed, 
the potential use of immune -based therapy to treat advanced CCA and PDAC has only recently 
been investigated.  
The tumor microenvironment in PDAC is remarkable for its profound desmoplasia, absence of  
effector T cells and its T helper 2 (Th2) cell immunophenotype, which contribute to its ability to 
avoid immune surveillance [49, 50].  Many strategies to modulate the tumor microenvironment to 
a Th1 cell immunophenotype are under study: vaccination to in duce or reinforce pre -existing 
immune responses is being investigated with agents such as GVAX (autologous pancreatic cell 
lines transfected with granulocyte –macrophage colony -stimulating factor) or CRS ‑207 (live 
attenuated Listeria monocytogenes -expressin g mesothelin) alone or with a checkpoint inhibitor; 
directed cytolysis using T cells expressing chimeric antigen receptors; oncolytic virus therapy, to 
name [CONTACT_308096] a few [51 -54].    
  
  
  
  
  
23  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
So far, treating PDAC with single -agent immune checkpoint inhibitors has no t been effective [55, 
56]. In prior studies, it was shown that membranous PD -L1 expression is scarce in PDACs [57], 
and since PD -L1 expression is shown to be activated in either by [CONTACT_308057], particularly interferon g amma, as a result of adaptive immune response, 
this low expression can be secondary to the lack in PDAC of effective T cell infiltration, as stated 
above [58, 59].  
  
Evidence emerged recently that many genetic alterations in PDAC target epi[INVESTIGATOR_308006] [60, 
61, 62]. In PDAC recent whole genomic sequencing revealed pathogenic mutations, structural 
variants and aberrant expression in several epi[INVESTIGATOR_308007]6A , ARID1A , 
ARID1B , PBRM1 , SMARCA2 , SMARCA4 , and MLL2  [31, 63].  Importa ntly, drug resistance in 
PDAC is mediated by [CONTACT_308058]. The dynamic character of cell 
plasticity and drug resistance suggest s the involvement of epi[INVESTIGATOR_308008] [64].  
Nevertheless, recent translational research activities propose that combining modulation of the 
immune response and pharmacological targeting of epi[INVESTIGATOR_308009] [65].  
  
It has been demonstrated that PDL1 expression is present in a majority of CCA patients at baseline 
(49-94%), and is associated with poor survival, which suggests t hat CCA may be particularly 
sensitive to this strategy [66, 67]. In the study by [CONTACT_308059]. the expression of PD -L1 within the 
tumor front was associated with an almost 60% worse survival [68]. These findings are very 
interesting insofar PD -L1 is an argua ble biomarker for sensitivity to immune checkpoint inhibitors. 
Indeed, several clinical trials have investigated the potential role of immunotherapy in this 
malignance. Investigators at National Institute of Health (NIH) used a whole -exomic -
sequencingbased  approach to demonstrate that TILs from a patient with metastatic CCA contained 
CD4+Th1 cells recognizing a mutation in erbb2 interacting protein ( ERBB2IP ). After adoptive 
transfer of TILs containing mutation -specific polyfunctional TH1 cells, the patient achieved 
prolonged partial response. Upon disease progression, the patient was retreated with mutation -
reactive TH1 cells and again experienced tumor regression [69].   
  
  
  
  
  
24  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Patients with MSI -H CCA who received pembrolizumab (an anti -PD-1) had a 71% objective 
response rate (ORR) and 67% progression free survival (PFS) [70]. Preliminary limited activity of 
immune checkpoint inhibitors in this disease is supported also by a phas e 1B trial with 
pembrolizumab (Keynote 028), enrolling only patients with positive PD -L1 tumor expression, that 
reported a 17% ORR among CCA patients [71]. This result indicates that PD -[ADDRESS_376895] but real activity in CCA and merit further in vestigation  
  
Interestingly, exome sequencing in iCCA showed frequent mutations in genes involved in 
chromatin remodeling such as BAP1 , ARID1A , and PBRM1  [33]. Moreover, it has been established 
that IDH1/2 mutations in CCA impair the activity of TET famil y of DNA dioxygenases resulting 
in a decrease of cytosine hydroxymethylation with a concurrent increase of DNA methylation [72]. 
The epi[INVESTIGATOR_308010]1/2 mutations lead to a blockade of cellular 
differentiation, causing an increase in th e progenitor cells [73].   
  
At the current time, there are no proven therapi[INVESTIGATOR_308011]. In our 
opi[INVESTIGATOR_1649], HDAC inhibitors may offer therapeutic value and need further investigation.    
  
All together these findings have reinforced  the potential role of immune therapy and epi[INVESTIGATOR_308012], and they paved the way forward for investigating their appropriate 
combination in improving patient outcomes.  
  
2.5 Investigational Agents  
  
2.5.1 Entinostat (SNDX 275)  
  
Entinostat belongs to the class of HDAC inhibitors which are critically important in the regulation 
of gene expression and in the field of target -specific anticancer drug development [34]. Entinostat 
is a member of the substituted pyridylcarbamate class of  HDAC -inhibiting compounds with oral 
bioavailability [37, 38]. It selectively inhibits class I and IV HDACs, specifically, HDACs 1, 2, 3, 
and 11, thus promoting hyperacetylation of histones and allowing transcriptional activation of a 
distinct set of genes , ultimately inhibiting cell proliferation, terminal differentiation, and/or 
  
  
  
  
25  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
apoptosis. This isoform selectivity may differentiate the safety and efficacy profiles from those of 
nonselective pan -HDAC inhibitors.  
  
In addition, entinostat has demonstrated immunomodulatory activity that may translate to direct 
effects on the TME and enhanced antitumor immune responses [35, 36, 39].   
  
 
   2.5.2 Nonclinical Development of Entinostat  
  
  
  
  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
26  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 2.5.3   Clinical Development of Entinostat  
  
  
  
  
  
  
  
  
  
  
  
27  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
   
  
  
  
  
  
  
  
   
  
  
  
  
              
  
  
   
  
  
  
  
  
   
  
2.5.4   Entinostat in Combination  
  
28  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
     
  
  
  
  
   
 Nivolumab (BMS -936558)  2.5.5  
  
  
  
  
  
  
     
  
  
  
  
  
  
  
  
    
  
  
  
  
  
  
  
  
    
  
  
  
  
  
  
29  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 
 
  
   
  
  
  
  
  
  
  
  
  
2.5.6   Nonclinical Development of Nivolumab  
2.5.7   Clinical Development of Nivolumab  
  
  
  
  
  
   
  
  
  
30  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
     
  
   
  
  
  
  
  
  
  
    
  
  
  
  
      
  
  
  
  
   
  
  
  
  
  
  
  
31  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
     
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
32  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic  Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
     
  
2.6 Entinostat in Combination with PD -1 Checkpoint Inhibition: Rational of the Study   
  
One potential strategy for improving response to immune checkpoint inhibitors is to prime the 
tumor with an epi[INVESTIGATOR_278211]. Perhaps uniquely in the human body, the immune system is 
comprised of a complex network of interacting cells that is highly resp onsive and often stably 
adaptive to environmental cues.   
Understandably, therefore, acknowledgments about the precise relationships between epi[INVESTIGATOR_308013], immune system and the consequences for cancer cell phenotypes could have 
tremendously impor tant translational implications [95, 96]. Importantly, epi[INVESTIGATOR_308014] [13, 27, 
29].    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
 
   
 
    
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
     
  
  
  
  
  
 
 28  
J1798/Version 5.0/May 21, 2020   
  
38  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
   
  
  
  
  
  
  
  
  
   
  
  
  
  
  
  
40  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
3. PATIENT SELECTION  
  
3.[ADDRESS_376896] therapy or is intolerant of therapy; 1 or 2 prior chemotherapy regimens 
in the metastatic setting or progression < 6 months from the completion of adjuvant 
chemotherapy.   
  
3.1.2.  Age ≥18 years.   
  
3.1.3.  ECOG performance status of 0 or 1 (Karnofsky ≥70%, see Appendix A ).  
  
3.1.4.  Life expectancy of greater than [ADDRESS_376897] normal organ and marrow function as defined below:   
• Hemoglobin (HgB)    ≥ 9.0 g/dL  
• Leukocytes    ≥ 3,000/mcL  
• Absolute neutrophil count  ≥ 1,500/mcL  
• Platelets    ≥ 100,000/mcL  
• Total bilirubin  ≤ 1.5 x institutional upper limit of normal (ULN);  an exception to 
this may be allowed for participants with Gilbert’s syndrome with documented 
approval by [CONTACT_36476]  
• AST(SGOT)/ALT (SGPT)  ≤ 3 × institutional ULN  
• Creatinine    within normal institutional limits  
or  
• Creatinine clearance  ≥ 60 mL/min using the Modified Cockcroft -Gault, as the 
formula below:   
Female CrCl = (140 - age in years) x weight in kg x 0.85  
                              72 x serum creatinine in mg/dL  
  
Male CrCl = (140 - age in years) x weight in kg x 1.00   
  
  
41  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
72 x serum creatinine in mg/dL  
  
3.1.6.  Negative (serum or urine)  pregnancy test, for women of childbearing potential.  NOTE: 
If a patient has a positive or indeterminate serum or urine pregnancy test, then an 
ultrasound must be done to rule out pregnancy to enroll on trial. A serum B -HCG value  
of <[ADDRESS_376898] 1.1. (see Section 8.1 )    
  
3.1.8.  Patient must have an accessible non -bone tumor lesion from which serial core biopsy 
specimens can be obtained.   
NOTE : Patients with bone only disease are not eligible due to difficulties in obtaining 
serial bone biopsies for correlative analyses.      
  
3.1.9.  Women of child -bearing potential (WOCBP) and men must agree to use adequate 
contraception (hormonal or barrier method of birth control; abstinence) prior to study 
entry and during all the period of study participation for at least [ADDRESS_376899] dose of nivolumab (see Section 4.7.2 ).  WOCBP must have a negative serum or 
urine pregnancy test (minimum se nsitivity 25 IU/L or equivalent units of HCG) at 
baseline.  Women must not be breastfeeding.  Women who are not of childbearing 
potential (e.g., who are postmenopausal or surgically sterile as well as azoospermic men) 
do not require contraception. NOTE: If  a patient has a positive or indeterminate serum 
or urine pregnancy test, then an ultrasound must be done to rule out pregnancy to enroll 
on trial. A serum B -HCG value of <[ADDRESS_376900] not recovered from adverse events due to prior administered agents as follows:   
  
  
42  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• Chemotherapy < 3 weeks prior to registration  
• Targeted therapy (other than below ) < 2 weeks prior to registration   
• Radiotherapy < 3 weeks prior to registration ( NOTE:   A previously irradiated 
lesion may not be used as a target lesion unless there is evidence of post -radiation 
progression.)  
• Surgery < 3 weeks prior to registration  
• Other approved or investigational agents <3 weeks prior to registration unless 
otherwise noted by [CONTACT_36476].  
• Patients who have received prior epi[INVESTIGATOR_278211] (e.g. HDAC inhibitors such as  
entinostat, panobinostat, vorinostat, romidepsin or deme thylating agents such as 
5azacitidine or decitabine)   
• Those who have not recovered from acute adverse events to grade <2 or baseline 
due to agents administered, with exception of alopecia or stable neuropathy, unless 
approved by [CONTACT_36476].  
  
3.2.2 Patients with a history of prior treatment with anti -PD-1, anti -PD-L1, anti -PD-L2, 
antiCTLA4 antibodies or any other antibody or drug specifically targeting T -cell 
costimulation or immune checkpoint pathways.   
  
3.2.3 Known sensitivity to or history of allergic reactions attributed to compounds of similar 
chemical or biologic composition of entinostat and/or nivolumab.  History of severe 
hypersensitivity reaction to any monoclonal antibody.   
  
3.2.[ADDRESS_376901] vital organ function or require immune suppressive treatment 
including systemic corticosteroids, should be excluded.  These include but are not limi ted 
to patients with a history of immune related neurologic disease,  multiple sclerosis, 
autoimmune (demyelinating)  neuropathy, Guillain -Barre syndrome, myasthenia gravis; 
systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, 
inflammatory bowel disease (IBD), Crohn’s, ulcerative colitis, autoimmune hepatitis; 
and patients with a history of toxic epi[INVESTIGATOR_194] (TEN), Stevens -Johnson 
syndrome, or phospholipid syndrome should be excluded because of the risk of 
recurrence or  exacerbation of disease.  Patients with vitiligo, endocrine deficiencies 
including thyroiditis managed with replacement hormones including physiologic 
  
  
43  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
corticosteroids are eligible.  Patients with rheumatoid arthritis and other arthropathies, 
Sjögren’s syn drome and psoriasis controlled with topi[INVESTIGATOR_308015], such as antinuclear antibodies (ANA), anti -thyroid antibodies should 
be evaluated for the presence of target organ involvement and potential need for systemic 
treatment but should otherwise be eligible.    
  
NOTE:  Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, 
residual hypothyroidism due to autoimmune condition only requiring hormone 
replacement, psoriasis not requiring systemic tre atment, or conditions not expected to 
recur in the absence of an external trigger (precipi[INVESTIGATOR_124372]).  
  
3.2.5 Subjects with interstitial lung disease that is symptomatic or may interfere with the 
detection or management of suspected drug -related pulmon ary toxicity.    
  
3.2.6  Patient has a pulse oximetry of <92% on room air or is on supplemental home oxygen.   
  
3.2.7 Patients with active or untreated brain metastases or leptomeningeal metastases are 
excluded from this clinical trial because of their poor prognosis and because they often 
develop progressive neurologic dysfunction that would confound the evaluation of 
neurologic and other adverse events.     
  
NOTE:  Patients with previously treated brain metastases must have stable neurologic 
status and imaging following local therapy (surgery or radiation) for at least 4 weeks, 
with no requirement for immunosuppressive do ses of systemic corticosteroids (>10 
mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration 
(stable low dose dexamethasone allowed at discretion of IND Sponsor).    
  
3.2.8 Uncontrolled intercurrent illness including, but no t limited to, ongoing or active infection, 
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or 
psychiatric illness/social situations that in the judgment of the investigator would limit 
compliance with study requirements.   
  
3.2.[ADDRESS_376902] the potential for 
teratogenic or abortifacient effects.  Because there is an unknown but potential risk for 
  
  
44  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
adverse events in nursing infants secondary to treatment of the mother , breastfeeding 
should be discontinued.   
  
3.2.[ADDRESS_376903] for hepatitis B virus surface antigen (HBV sAg) or 
hepatitis C antibody (HCV Ab)/RNA (HCV  RNA) indicating acute or chronic infection 
are also ineligible (baseline testing required).     
  
3.2.[ADDRESS_376904] a condition requiring systemic treatment with 
either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive 
medications within 14 days of study drug administration.  Inhaled or topi[INVESTIGATOR_119338] <10 mg daily prednisone equivalents are permitted in the 
absence of active autoimmune disease.  Patients are permitt ed to use topi[INVESTIGATOR_2855], ocular, 
intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic 
absorption).  Physiologic replacement doses of systemic corticosteroids are permitted, 
even if <10 mg/day prednisone equivalents.  A brief course  of corticosteroids for 
prophylaxis (e.g., contrast dye allergy) or for treatment of non -autoimmune conditions 
(e.g., delayed -type hypersensitivity reaction caused by [CONTACT_13132]) is permitted.     
  
3.2.[ADDRESS_376905] had evidence of active or acute diverticulitis, intra -abdominal abscess, 
or GI obstruction which are known risk factors for bowel perforation shoul d be evaluated 
for the potential need for additional treatment before coming on study.   
  
3.2.14 Any contraindication to oral agents or significant nausea and vomiting, malabsorption, 
or significant small bowel resection that, in the opi[INVESTIGATOR_88079], would 
preclude adequate absorption.   
  
3.2.15 Another active malignancy ≤ 3 years prior to registration with the exception of 
nonmelanotic skin cancer or carcinoma -in-situ of any type.  NOTE:  If there is a history 
of prior malignancy, they must not  be receiving other specific treatment for their cancer.  
Any malignancy considered to be indolent and that has never required therapy may 
allowed at the discretion of the IND Sponsor .  
  
  
45  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
3.2.16 Patient is unwilling or unable to follow the study schedule f or any reason.   
  
3.2.17 Patient is, at the time of signing informed consent, a regular user (including “recreational 
use”) of any illicit drugs or other substance abuse (including alcohol) that could 
potentially interfere with adherence to study procedure s or requirements.   
  
3.2.18 Evidence of clinical or radiographic ascites. Trace or small amounts of radiographic 
ascites without prior concern for malignant ascites or not associated with peritoneal 
carcinomatosis may be approved by [CONTACT_407]. NO TE: [ADDRESS_376906] reads will not be used to determine eligibility at baseline.   
  
3.3 Inclusion of Women and Minorities  
  
NIH policy requires that women and members of minority groups and their subpopulations be 
included in all NIH -supported biomedical and behavioral research projects involving NIH -defined 
clinical research unless a clear and compelling rationale and justific ation establishes to the 
satisfaction of the funding Institute & Center (IC) Director that inclusion is inappropriate with 
respect to the health of the subjects or the purpose of the research.  Exclusion under other 
circumstances must be designated by [CONTACT_25513], NIH, upon the recommendation of an IC 
Director based on a compelling rationale and justification.  Cost is not an acceptable reason for 
exclusion except when the study would duplicate data from other sources.  WOCBP should not be 
routinely exclud ed from participation in clinical research.   
  
4. TREATMENT PLAN  
  
4.1 Agents Administration  
  
Treatment will be administered on an outpatient basis.  Reported adverse events and potential risks 
are described in Section 6 .  Appropriate dose modifications are described in Section 5 .    
  
No investigational or commercial agents or therapi[INVESTIGATOR_110634]'s malignancy.    
  
  
  
46  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
The cycle length is [ADDRESS_376907] of the combination of entinostat and nivolumab. 
A lead -in of entinostat 2 weeks prior to combination therapy at the dose of 5 mg/weekly, will be 
incorporated to help determine the effect of entinostat on immune -related parameters i n tumor 
biopsies.  
  
4.2 Overall Study Design  
  
The proposed study single institution, open -label, two -stage, phase 2 study evaluating the clinical 
activity and safety of entinostat plus nivolumab. We will enroll two cohorts of patients: 
unresectable or m etastatic cholangiocarcinoma (Cohort 1) and unresectable or metastatic 
pancreatic adenocarcinoma (Cohort 2). The primary objective of the trial is to determine whether 
the combination of entinostat plus nivolumab yields a clinically compelling antitumor ac tivity 
measured as objective response rate (ORR, assessed by [CONTACT_393] 1.1).   
  
Secondary endpoints include safety, progression -free survival (PFS), overall survival (OS), and 
immunologic correlates.   
  
The study is planned with 27 evaluable subjects per hi stology based on a two -stage design that 
allows early termination for lack of efficacy.  
  
Patients will receive a biopsy at baseline and on approximately day 14 of entinostat therapy and 
approximately after 6 weeks from Cycle 1 Day 1. An optional biopsy will be performed at the time 
of disease progression. After a fourteen -day lead in with enti nostat monotherapy, patients will 
begin to concurrently receive entinostat 5 mg oral once a week plus nivolumab 240 mg every two 
weeks for approximately four months. After 4 months, nivolumab will be given at a dose of 480 
mg fixed dose every 4 weeks (main tenance phase). Therapy may continue with entinostat 5 mg 
weekly plus nivolumab 480 mg every 4 weeks, until intolerance or progression. Nivolumab will 
be administered intravenously over a period of 30 minutes.  
  
4.3 Definition of Unacceptable Toxicities  
  
Unacceptable toxicities are defined as treatment -related:   
  
• Grade 3 or greater non -hematologic toxicities. Exceptions include:  
  
  
47  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
- Grade 3 nausea/vomiting if improved to Grade 2 levels or better within 72 hours  
- Asymptomatic laboratory abnormalities  
- Grad e 3 fatigue  
- Grade 3 dermatologic AEs that are considered mild in severity but only considered 
grade 3 because of >30% body surface involvement  
- Grade 3 pruritus  
- Grade 3 -4 hyperglycemia or grade 3 endocrinopathies where symptoms are 
controlled on hormone replacement therapy  
• Febrile neutropenia Grade 3 or Grade 4:  
- Grade 3 is defined as ANC <1.0×109/L with a single temperature of >38.3°C 
(101°F) or a sustained temperature of ≥38°C (100.4°F) for more than 1 hour  
- Grade 4 is defined as ANC <1.0×109/L with a single temperature of >38.3°C 
(101°F) or a sustained temperature of ≥38°C (100.4°F) for more than 1 hour, with 
life-threatening consequences and urgent intervention indicated.  
• Grade 4 thrombocytopenia (i.e., platelet count <25×109/L)  
• Grade 3 thrombocytopenia with clinically significant bleeding  
• Any other toxicity resulting in a dose reduction in therapy (at the discretion of the IND 
Sponsor)  
• Failure to complete all protocol specified treatment doses (at the discretion of the IND 
Spon sor) • Concurrent elevation of transaminases and bilirubin consistent with Hy’s Law criteria  
Note: The original Hy's Law parameters for treated patients relative to comparator patients have 
been broadened over time (Kaplowitz and DeLeve 2003, Zimmerman 19 99) to include additional 
parameters, but still require that these 3 criteria be met:  
i. injury: elevation of >3×ULN ALT or AST activity; and ii.function: >2×ULN total 
bilirubin (another clinical marker for function, such as >1.5×ULN INR may be acceptable  
if the change is clinically significant in the absence of obstruction) without >2×ULN 
alkaline phosphatase (ALP); and iii.clinical verification to ensure effect is health product -
induced and not induced by [CONTACT_308060].  
• Grade 5 toxicity  
  
4.4 Study Drugs  
  
NOTE :  Subjects will be given an information sheet and wallet card to remind them of serious 
risks and that may be shared with their other healthcare providers, including a reminder to notify 
  
  
48  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
us of all new medications  started during the course of the study due to the possibility for drug 
interactions ( Appendix B ).    
 
  
4.3.1 Nivolumab (OPDIVO ®, BMS -936558; MDX -1106)   
 4.4.1   Entinostat (MS -275, SNDX -275)  
  
  
  
  
  
  
  
   
  
  
  
  
  
  
   
  
  
   
  
  
  
   
  
  
  
   
  
  
  
  
  
50  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Hypersensitivity reactions should be managed as per standard of care at the treating institution. 
Severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, 
angioedema or generalized urticaria require immediate discontinu ation of study drug 
administration and aggressive symptomatic therapy.   
Subjects who experience a severe hypersensitivity reaction to treatment should not be 
rechallenged.  
  
[IP_ADDRESS] Nivolumab  
  
Nivolumab is a fully human monoclonal immunoglobulin (Ig) G [ADDRESS_376908] with fever, chills, rigors, headache, rash, pruritus, arthralgia, hypo - or 
hypertension, bronchospasm, or other symptoms. All grade 3 or 4 infusion reactions should be 
reported within 24 hours to the IND Sponsor and BMS and Syndax as an SAE if the criteria are 
met. Infusion reactions should be graded according to CTCAE (version 4.03) guidelines. 
Treatment recommendations are provided below and may be modified b ased on local treatment 
standards and guidelines as appropriate:  
  
• For Grade 1 symptoms : (Mild reaction; infusion interruption not indicated; intervention 
not indicated).  
Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 
mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 minutes 
before additional nivolumab administrations.  
  
• For Grade 2 symptoms : (Moderate reaction requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [e.g, antihistamines, non -steroidal 
antiinflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; 
prophylactic medications indi cated for 24 hours).  
  
  
  
51  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject 
with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until r esolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion rate when 
symptoms resolve; if no further complications ensue  after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur 
then no further nivolumab will be administered at that visit. Administer diphenhydramine 
[ADDRESS_376909] be recorded on the electronic case report form (eCRF). 
The following prophylactic premedications are recommended for future infusions: 
diphenhydramine 50 mg (or equivalent)  and/or paracetamol 325 to 1000 mg 
(acetaminophen) should be administered at least 30 minutes before additional nivolumab 
administrations. If necessary, corticosteroids (recommended dose: up to 25 mg of IV 
hydrocortisone or equivalent) may be used.   
  
• For Grade 3 or Grade 4 symptoms:  (Severe reaction, Grade 3: prolonged [e.g., not rapi[INVESTIGATOR_20309]/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospi[INVESTIGATOR_308016] [eg, renal impairment, pulmonary infiltrates]). Grade 4 : (life threatening; pressor 
or ventilatory support indicated).   
Immediately discontinue infusion of nivolumab. Begin an IV infusion of normal saline, 
and treat the subject as follows. Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 mg of a 
1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or e quivalent), as needed. Subject should be monitored 
until the investigator is comfortable that the symptoms will not recur.   
Nivolumab will be permanently discontinued. Investigators should follow their 
institutional guidelines for the treatment of anaphyl axis. Remain at bedside and monitor 
subject until recovery from symptoms. In the case of late -occurring hypersensitivity 
symptoms (eg, appearance of a localized or generalized pruritus within 1 week after 
treatment), symptomatic treatment may be given (eg,  oral antihistamine, or 
corticosteroids).   
  
  
  
52  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
In the case of late -occurring hypersensitivity symptoms (e.g., appearance of a localized or 
generalized pruritus within 1 week after treatment), symptomatic treatment may be given (e.g., 
oral antihistamine, or corticosteroids). Additional treatment prior to next dose as per guidelines 
above.  
  
Please note that late occurring events including isolated fever and fatigue may represent the 
presentation of systemic inflammation.  Please evaluate accordingly.  
  
Nivo lumab -related infusion reactions and adverse events must resolve prior to administration of 
entinostat.  
  
4.5.3 Prohibited and Restricted Therapi[INVESTIGATOR_308017]:  
  
• Any non -study anticancer or immunotherapy agent (investigational or non -investigational). 
NOTE : With approval of the IND Sponsor subjects may receive palliative radiation therapy 
as long as a site(s) disease outside of the radiation field is available to f ollow for response. No 
study drug should be given during radiation therapy.  
  
• Concomitant use of valproic acid is prohibited due to its known activity as a HDAC inhibitor.  
  
• CD137 or other immunologic activation agonists.  
  
• Immunosuppressive agents.  
  
• Chronic systemic corticosteroids at supraphysiologic doses.   
  
NOTE : Subjects are permitted to use topi[INVESTIGATOR_2855], ocular, intra -articular, intranasal, and 
inhalational corticosteroids (with minimal systemic absorption).    
Physiologic replacement doses of syste mic corticosteroids are permitted, in the absence of 
active autoimmune disease.    
  
A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy), for treatment of 
non-autoimmune conditions (e.g., delayed -type hypersensitivity reaction caused by [CONTACT_54516] 
  
  
53  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
allergen), and for treatment of infusion reactions and premedication (e.g., up to 25 mg IV 
hydrocortisone) is permitted.  
  
Otherwise, steroid treatment should be completed at least 14 days prior to resuming 
studyrelated treatments unless approval to resume sooner is obtained from the IND Sponsor.  
  
• Live vaccines (examples  of live vaccines include, but are not limited to: measles, mumps, 
rubella, chicken pox, yellow fever, rabies, BCG, and typhoid [oral] vaccine). Seasonal 
influenza vaccines for injection are generally killed virus vaccines and are allowed. However, 
intrana sal influenza vaccines (e.g. Flu -Mist®) are live attenuated vaccines, and are NOT 
allowed.  
  
• The use of anticoagulants is known to increase the risk of gastrointestinal hemorrhage. Since 
gastrointestinal hemorrhage is an adverse reaction with nivolumab, s ubjects who require 
concomitant anticoagulant therapy should be monitored closely.  
  
• Concomitant use of the drugs below with entinostat should be avoided during the study (also 
listed in Appendix E ):  
• Sensitive substrates of CYP1A2, CYP2C8, CYP3A with a  narrow therapeutic window  •  
Drugs that are known to inhibit or induce P -gp   
  
4.5.4 Precautions  
  
Combination therapy may result in unexpected toxicity especially in novel combinations with 
other immune modifying agents.  A striking example in macaques is presented in Vaccari, et al.  
2012 [120].  
  
4.[ADDRESS_376910] be 
reported as SAEs (see Section 6.6 ).  
  
  
  
54  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
4.7 WOCBP, Contraception, Us e in Pregnancy, Use in Nursing  
  
4.7.1 WOCBP  
  
A WOCBP is defined as any female who has experienced menarche and who has not undergone 
surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal. 
Menopause is defined as [ADDRESS_376911] a serum follicle stimulating hormone (FSH) level > 40mIU/mL to confirm menopause. 
Women trea ted with hormone replacement therapy (HRT) are likely to have artificially suppressed 
FSH levels and may require a washout period in order to obtain a physiologic FSH level. The 
duration of the washout period is a function of the type of HRT used. The dura tion of the washout 
periods below are suggested guidelines and the investigators should use their judgment in checking 
serum FSH levels. If the serum FSH level is >40 mIU/ml at any time during the washout period, 
the woman can be considered postmenopausal:   
  
• 1 week minimum for vaginal hormonal products (rings, creams, gels)  
• 4 week minimum for transdermal products  
• [ADDRESS_376912] -feeding women ma y be enrolled if they are 
considered highly unlikely to conceive. Highly unlikely to conceive is defined as 1) surgically 
sterilized, or 2) postmenopausal, or 3) amenorrheaic for <2 years without a hysterectomy and 
oophorectomy and with a documented FSH va lue in the postmenopausal range, or 4) not 
heterosexually active for the duration of the study, or 5) heterosexually active and willing to use 2 
methods of birth control (which is also required for the female partners of male subjects). The [ADDRESS_376913] 
  
  
55  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
dose of study medication.  Male subjects enrolled in this study must also agr ee to use an adequate 
method of contraception starting with Visit [ADDRESS_376914] 
a failure rate of < 1% per year when used consistently and correctly.  
  
[IP_ADDRESS] Highly Effective Methods of Contraception  
  
• Male condoms with spermicide.  
  
• Hormonal methods of contraception including combined oral contraceptive pi[INVESTIGATOR_3353], vaginal ring, 
injectables, implants, a nd intrauterine devices (IUDs) such as Mirena by [CONTACT_118115]’s WOCBP partner.  
  
• Nonhormonal IUDs, such as ParaGard.  
  
• Tubal ligation.  
  
• Vasectomy.  
  
• Complete abstinence.  
  
Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an 
acceptable form of contraception for all study drugs. Abstinence is only acceptable when this is in 
line with the preferred and usual lifestyle of the subject. Perio dic abstinence (e.g., calendar, 
ovulation, symptothermal, profession of abstinence for entry into a clinical trial, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception. Subjects who choose 
complete abstinence are not required  to use a second method of contraception, but female subjects 
must continue to have pregnancy tests. Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject chooses to forego complete 
abstinence. NOTE:  If a patient has a positive or indeterminate serum or urine pregnancy test, then 
  
  
56  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
an ultrasound must be done to rule out pregnancy to enroll on trial. A serum B -HCG value of <[ADDRESS_376915].  
  
Subjects should be informed that t aking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur during the study.  In order to participate in the 
study they must adhere to the contraception requirement (described above) for the duration of the 
study.  If there is any question that a subject will not reliably comply with the requirements for 
contraception, that subject should not be entered into the study.  
  
4.7.[ADDRESS_376916] adver se effects on a fetus; therefore, 
women with a positive pregnancy test at screening will not be eligible for enrollment.  If a subject 
inadvertently becomes pregnant while on treatment, the subject will immediately be removed from 
the study treatment.  The  study team will contact [CONTACT_308061]’s status until the pregnancy has been completed or terminated.    
  
The investigator must immediately notify the Syndax Sponsor and BMS of any pregnancy using 
the Pregnancy Surveillance Form within [ADDRESS_376917] unless contraindicated by [CONTACT_8663] (e.g. x -ray studies). Other appropriate 
pregnancy follow -up procedures should be considered if indicated.   
  
Follow -up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and where applicable, offspring information must be  reported on the Pregnancy 
Surveillance Form.   
4.7.[ADDRESS_376918] -feeding are not eligible fo r enrollment.  
  
  
  
57  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
4.8 Duration of Treatment and Criteria for Removal from Treatment  
  
In general, treatment will continue until one of the following criteria are met:  
  
• Disease progression. NOTE :  Treatment may continue under the guidelines discussed in 
Section 4.9 , as per opi[INVESTIGATOR_308018].  
  
• The patient or legal representative (such as a parent or legal guardian) withdraws consent 
for treatment but not follow up.  
  
• Intercurrent illness that prevents further administration of treatment.  
  
• Unacceptable adverse events. If the study treatment has provided clinical benefit, the IND 
sponsor may approve trial continuation for patients experiencing entinostat -related 
toxicities that are not life threatening or of major clinical concern (such as pr uritis or rash). 
NOTE : Assessment for discontinuation of entinostat may be made independently of 
nivolumab, continuation of entinostat may be considered with approval by [CONTACT_308062]. There are instances where treatment with nivolumab may continue if en tinostat 
has been discontinued. ( Section 5.1)   
   
• If in the opi[INVESTIGATOR_689], a change or temporal or permanent discontinuation of 
therapy would be in the best interest of the patient.  The Sponsor should be included in this 
decision.  
  
• Noncomp liance with trial treatment or procedure requirements.  
  
• Patient becomes pregnant. All women of child bearing potential should be instructed to 
contact [CONTACT_28265] (e.g., missed 
or late menstrual per iod) at any time during study participation. The investigator must 
immediately notify CTEP in the event of a confirmed pregnancy in a subject participating 
in the study.  
  
• Treatment required with other chemotherapeutic or investigational anti -neoplastic d rugs.  
  
  
  
58  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• Patient is lost to follow -up.  
  
• In the case that a participant develops intolerance or side effect that is attributable to entinostat, 
the participant may, at his or her discretion, continue to receive only Nivolumab as otherwise 
indicated as long as they have received at least 1 full do se of both entinostat and nivolumab 
and nivolumab re -treatment criteria are met as outlined above.   
  
• If nivolumab has to be permanently discontinued because drug -related toxicity, the patient will 
be permanently discontinued from entinostat treatment too .   
  
The subject must be discontinued from the trial for any of the following reasons:  
  
• The patient or legal representative (such as a parent or legal guardian) withdraws consent 
for follow -up.  
  
• Termination of the study.  
  
• Patient is lost to follow u p.  
  
The reason for study removal and the date the subject was removed must be documented in the 
Case Report Form .  
  
4.9 Treatment Beyond Progression  
  
A minority of subjects treated with immunotherapy may derive clinical benefit either delayed 
responses, stable disease, or increased overall survival despi[INVESTIGATOR_222048] (PD) with nivolumab or combination treatment.    
  
Subject s may be permitted to continue treatment beyond initial RECIST 1.1 -defined PD as long 
as the following criteria are met:  
  
• Patients must be clinically stable with no change in performance status due to disease 
progression.  
  
  
  
59  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• No indication for immediate a lternative treatment  
  
• Patient [assessed by [CONTACT_093]] is showing clinical benefit and tolerates study drug.  
The assessment of clinical benefit should take into account whether the subject is clinically 
stable or deteriorating and likely or unlike ly to receive further benefit from continued 
treatment  
  
• The time of progression is noted from the first assessment that exceeds standard criteria 
All decisions to continue treatment beyond initial progression must be discussed with the 
PI [INVESTIGATOR_308019], including if for any exception to the criteria noted above.  
  
New lesions are considered measurable at the time of initial progression if the longest diameter is 
at least 10 mm (except for pathological lymph nodes, which must have a short axis of at least 15 
mm).  Any new lesion considered non -measurable at the tim e of initial progression may become 
measurable and therefore included in the tumor burden measurement if the longest diameter 
increases to at least 10 mm (except for pathological lymph nodes, which must have an increase in 
short axis to at least 15 mm).  
  
For statistical analyses that include the investigator -assessed progression date, subjects who 
continue treatment beyond initial investigator -assessed, RECIST 1.[ADDRESS_376919] -defined progression (e.g., irRC) 
will be also summarized separately.  
    
4.[ADDRESS_376920] from study therapy is 
made (no further treatment with study therapy).  
  
All subjects who discontinue investigational product should comply with protocol specified 
follow -up procedures a s outlined in Section 10, Study Calendar.   
  
A mandatory End of treatment (EOT) visit (+/ - 7 days) should be performed [ADDRESS_376921] 
dose of study drug(s).  
  
  
60  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
After completion of the EOT visit, subjects will be followed every 3 months for surviva l.  
  
Subjects who are discontinued from the study treatment due to an unacceptable toxicity will be 
monitored for safety until the resolution of the AE to ≤ grade [ADDRESS_376922] dose of the 
investigational agent through 100 days (+ 14 days) after the last dose of study drug or end of the 
study (if thought to be related to study drug), or 30 da ys after the initiation of a new anticancer 
therapy, whichever is earlier.    
5. DOSING DELAYS/DOSE MODIFICATIONS   
  
In order to maintain dose -intensity and cumulative dose -delivery on this study, reasonable efforts 
will be made to minimize dose reduction  and treatment delays as specified below.   
Although entinostat and immune checkpoint blockade have distinct toxicity profiles, they do share 
some adverse events such as fatigue, nausea and diarrhea. There is the theoretical possibility that 
one agent may potentiate the other and hence drug causality will not always be clear. In the event 
of uncertainty, dose reductions and/or delays will follow the most conservative approach.  
  
For any event which is apparent at baseline, the dose modifications will apply  according to the 
corresponding shift in toxicity grade, if the investigator feels it is appropriate (e.g., if a subject has 
grade 1 asthenia at baseline which increases to grade 2 during treatment, this will be considered as 
a shift of 1 grade and treated  as a grade 1 toxicity for dose modification purposes).   
  
All toxicity grades below are described using the NCI Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03.  
  
All discontinuations, relationships to treatment, and treatment decisions must be clearly 
documented in the medical record.  Any questions should be discussed with the IND Sponsor.    
  
Dose reductions due to toxicity are permanent. Dose escalation is not allowed. Dose 
reduction is not allowed for Nivolumab treatment.   
  
  
  
61  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
NOTE:   Tumor assessments should continue as per protocol even if dosing is delayed.  
  
5.[ADDRESS_376923]’s organ function and 
treatment -related toxicities must have recovered to the following values:   
  
• Absolute Neutrophil Count (ANC) ≥ 1,000 x 106/L   
  
• Platelets ≥ 75,000 x 106/L   
  
• Creatinine ≤ 1.[ADDRESS_376924] OR > 60 mL/min for patient with creatinine levels >1.5× 
institutional ULN.  
  
• Non-hematologic toxicities ≤ Grade 2 as noted below for entinostat -related toxicity 
Nivolumab  
  
Dosing of nivolumab will be delayed for any of the criteria listed below:  
• Total bilirubin ≥ 1.5×ULN (for patients with diagnosed Gilbert’s Syndrome, direct 
bilirubin should be within normal institutional limits).  
  
• Aspartate aminotransferase (AST) and al anine aminotransferase (ALT) > 3 ×ULN OR ≥5 
×ULN for patients with liver metastases: NOTE - appropriate evaluation for autoimmune 
transaminitis must be conducted  
  
• Any ≥ Grade 2 non -skin, non -laboratory, drug -related adverse event, with the following 
exception:  
  
• Grade 2 drug -related fatigue does not require a treatment delay.  
  
• Grade 2 hypothyroidism or thyroiditis does not require a treatment delay  
  
  
  
62  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• Subjects with Grade 3 thyroiditis or hypopi[INVESTIGATOR_308020].    
NOTE: grading for hypophysitis with symptoms of headache, visual or neurologic 
changes or  radiologic evidence of pi[INVESTIGATOR_308021] 3 events  
  
• Any ≥ Grade 3 skin, drug -related adverse event.  
  
• Any ≥ Grade 3 drug -related laboratory abnormality with t he following exceptions:  
  
• Grade 3 lymphopenia does not require dose delay  
  
• Any Grade ≥ 3 drug -related amylase or lipase abnormality that is not associated with 
symptoms or clinical manifestations of pancreatitis does not require dose delay.   
  
• Isolate d grade 3 or 4 electrolyte imbalances/abnormalities that are not associated  
  
  
71  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
- Concurrent AST or ALT ≥ 3 × ULN and total bilirubin > 2 × ULN, irrespective of 
baseline levels  
  
• Any Grade 4 treatment -related AE or laboratory abnormality, except for the following 
events which DO NOT require discontinuation:  
  
- Grade 4 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations, or radiographic signs of pancreatitis.   
- Isolated grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate management 
within 72 hours of their onset.  
- Grade 4 lymphopenia and leukopenia.   
- Grade 4 treatment -related endocrinopathy adverse events, such as ACTH deficiency, 
hyper - or hypothyroidism, or glucose intolerance,  which resolve or are adequately 
controlled with physiologic hormone replacement (corticosteroids, thyroid 
hormones) or glucose -controlling agents, respectively, may not require 
discontinuation after discussion with and approval from the Sponsors.  
  
• Grade  3 and 4 adrenal insufficiency require discontinuation  
  
• Any dosing interruption lasting >6 weeks, with the following exceptions: NOTE: Dosing 
interruptions >[ADDRESS_376925] the presence of ongoing immune activation and should require permanent discontinuation.  
  
• Any subjects who require additional immune suppressive treatment beyond steroids should 
go off study treatment  
  
If nivolumab has to be permanently dis continued because drug -related toxicity, the patient will be 
permanently discontinued from entinostat treatment too.   
  
  
  
72  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
In the case that a participant develops intolerance or side effect that is attributable to entinostat, 
the participant may, at his or h er discretion, continue to receive only Nivolumab as otherwise 
indicated as long as they have received at least 1 full dose of both entinostat and nivolumab and 
nivolumab re -treatment criteria are met as outlined above.  
  
  
  
  
  
6. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS   
  
6.1 Study Drugs  
  
6.1.1 Entinostat  
  
Commonly encountered AEs across clinical studies of entinostat monotherapy in patients with 
solid tumors included hypoalbuminemia, fatigue, nausea, hypophosphate mia, anemia, and 
thrombocytopenia. Incidence and severity were dose - and schedule -dependent. In a Phase 2, 
randomized, placebo -controlled study in patients with lung cancer, in which patients received 
erlotinib+entinostat or erlotinib+placebo, treatment -emergent adverse events (TEAEs) occurring 
at a ≥10% higher incidence in entinostat -treated patients versus placebo -treated patients included 
nausea (49% versus 25%); anorexia (40% versus 16%); weight decreased (32% versus 18%); 
dyspnea (31% versus 18%); vomi ting (31% versus 13%); peripheral edema (28% versus 13%); 
anemia (22% versus 11%); thrombocytopenia (15% versus 3%); hypotension (14% versus 2%); 
and stomatitis (12% versus 2%). In a Phase [ADDRESS_376926] common TEAEs were nausea (39%), hypophosphatemia 
(29%), pain in extremity (21%), and back pain and diarrhea (each 18%) [122].  Additional clinical 
experience is summarized in the entinostat IB.  
  
6.1.2 Nivolumab  
  
Blocking PD -1 function may permit the emergence of auto -reactive T cells and resultant clinical 
autoimmunity. Rash/pruritus, diarrhea/colitis, pneumonitis, hepatitis, and hypothyroidism were 
drug-related, presumptive autoimmune events noted in previous nivolumab studies.  
  
  
  
73  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
For the purposes of this study, a nivolumab -related AE is defined as an AE of unknown etiology, 
associated with drug exposure and is consistent with an immune phenomenon. Efforts should be 
made to rule out neoplastic, infectious, metabolic, toxin or oth er etiologic causes. Serological, 
immunological, and histological (biopsy) data should be used to support the diagnosis of an 
immune -mediated toxicity. Suspected nivolumab -related AEs must be documented on an AE CRF. 
Identification and treatment of nivolum ab-related AEs can be found in Section 4.4  as well as in 
Appendix D . Additional guidance can be found in the nivolumab IB.  
  
  
  
  
6.2 Adverse Events Definition  
  
6.2.1 Adverse Events   
  
An AE is defined in the International Conference on Harmonisation (ICH) Guideline for Good 
Clinical Practice as “any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and that does not necessar ily have a causal relationship 
with this treatment” (ICH E6:1.2).  
  
Worsening of a pre -existing medical condition, (e.g., diabetes, migraine headaches, gout) should 
be considered an AE if there is either an increase in severity, frequency, or duration of the condition 
or an association with significantly worse outcomes.  
  
Interventions for pretreatment conditions (e.g., elective cosmetic surgery) or medical procedures 
that were planned before study enrollment are not considered AEs.  
  
Disease progression  (PD) should not be recorded as an AE. If PD occurs, record the date first 
documented in the EOT visit eCRF. Also record all methods of assessment, e.g., 1 target/nontarget 
lesion, tumor response assessment, and/or clinical disease assessment. Indicate if the patient starts 
new treatment.  
  
In the case of death, only record “Fatal” for the event causing death. AEs that are ongoing at the 
end of the study or time of death are to be noted as “continuing.”   
  
  
  
74  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Classification of AEs is to be done by [CONTACT_308063], Version  
4.03. The Death eCRF must also be completed.  
  
The Investigator is responsible for reviewing laboratory test results and determining whether an 
abnormal value in an individual patient represents a significant  change from baseline. In general, 
abnormal laboratory findings without clinical significance (based on the Investigator’s judgment) 
should not be recorded as AEs; however, laboratory value changes requiring therapy or adjustment 
in prior therapy are consi dered AEs.  
  
6.2.2 Suspected Adverse Reactions   
  
A suspected adverse reaction is any AE for which there is a reasonable possibility that the drug 
caused the adverse event. For the purposes of Investigational New Drug Application (IND) safety 
reporting, ‘reasonable possibility’ means there is evidence to suggest a causal relationship between 
the drug and the AE. A suspected adverse reaction implies a lesser degree of certainty about 
causality than adverse reaction, which means any AE caused by a drug.  
  
6.2.3 Expectedness  
  
Unexpected AE:  An AE, which varies in nature, intensity or frequency from information on the 
investigational drug/agent provided in the product IB, package insert or safety reports. Any AE 
that is not included in the IB consent is con sidered “unexpected”.   
  
Expected (known) AE:  An AE, which has been reported in the IB. An AE is considered “expected”, 
only if it is included in the IB document as a risk.  
  
6.2.4 Serious Adverse Events  
An AE or suspected adverse reaction is considered  “serious” if, in the view of either the 
Investigator or Sponsor, it results in any of the following outcomes:   
• is fatal  
• is life -threatening (e.g., places the patient at immediate risk of death)  
• requires in -patient hospi[INVESTIGATOR_308022] >24 hours  
• results in persistent or significant disability/incapacity  
  
  
75  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• is a congenital anomaly/birth defect  
• is an important medical event that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_6931] a serious adverse drug experience when, based upon 
appropriate medical judgment, it may jeopardize the patient and may require  medical or 
surgical intervention to prevent one of the outcomes listed in this definition. Examples of 
such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do  not result in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
• Potential drug induced liver injury (DILI) is also considered an important medical event.   
• Hemophagocytic lymphohistiocytosis is also considered an important m edical event.  
• Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the 
study drug is an SAE.  
• Is a new cancer (that is not a condition of the study)  
• Is associated with an overdose  
• Is a pregnancy or pregnancy outcome of spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, or stillbirth.  
A hospi[INVESTIGATOR_37349] “serious” is any in -patient hospi[INVESTIGATOR_256170] a minimum of an overnight stay in a health care facility. Any AE that does 
not meet one of the definitions of serious (e.g., emergency room visit, out -patient surgery, or 
requires urgent investigation) may be consi dered by [CONTACT_139666] “other significant 
medical hazard” criterion for classification as a serious adverse event (SAE).  
  
6.3 Reporting Procedures for All Adverse Events  
  
The Investigator is responsible for ensuring that all AEs observed  by [CONTACT_308064]’ medical records and reported on the eCRF. The 
evaluation time period for all adverse events is from the first dose of the investigational agent to at 
least [ADDRESS_376927] be assigned by [CONTACT_737]:   
• event description (with detail appropriate to the event);   
  
  
76  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• seriousness;   
• dates of onset and resolution;   
• severity;  
• assessment of relatedness to entinostat and to nivolumab;  
   the action taken.   
Laboratory abnormalities: Laboratory abnormalities present at the screening visit will be recorded 
as pre -treatment signs and symptoms. After study treatment administration, all grade 3 and 4 
clinical laboratory results that represent an increase in severi ty from baseline will be reported as 
AEs. A grade 1 or 2 clinical laboratory abnormality should be reported as an AE only if it is 
considered clinically significant by [CONTACT_093] (induce clinical signs or symptoms or require 
therapy)  
  
The Investiga tor may be asked to provide follow -up information, discharge summaries, and 
extracts from medical records.  
  
If applicable, the study drug relationship will be assessed by [CONTACT_7859]: “Is there a 
reasonable possibility that the event may have b een caused by [CONTACT_308065]/or toxicity profile, or by [CONTACT_308066]?”  
The relationship of an AE to the administration of the study drug is to be assessed by [CONTACT_308067]:   
  
• No (unrelated, not related, no relation):  The time course between the administration of 
study drug and the occurrence or worsening of the adverse event rules out a causal 
relationship and another cause (concomitant drugs , therapi[INVESTIGATOR_014], complications, etc.) is 
suspected.   
  
• Yes (related): The time course between the administration of study drug and the occurrence 
or worsening of the adverse event is consistent with a causal relationship and no other cause 
(concomitant drugs,  therapi[INVESTIGATOR_014], complications, etc.) can be identified.   
  
The following factors should also be considered:   
• The temporal sequence from study drug administration - The event should occur after the 
study drug is given. The length of time from study drug expos ure to event should be 
evaluated in the clinical context of the event.   
  
  
77  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• Underlying, concomitant, intercurrent diseases - Each report should be evaluated in the 
context of the natural history and course of the disease being treated and any other disease 
the subject may have.   
• Concomitant medication - The other medications the subject is taking or the treatment the 
subject receives should be examined to determine whether any of them might be recognized 
to cause the event in question.   
• Known response patter n for this class of study drug - Clinical and/or preclinical data may 
indicate whether a particular response is likely to be a class effect.   
• Exposure to physical and/or mental stresses - The exposure to stress might induce adverse 
changes in the recipi[INVESTIGATOR_23567] a logical and better explanation for the event.   
The pharmacology and pharmacokinetics of the study drug - The known pharmacolog ic properties 
(absorption, distribution, metabolism, and excretion) of the study drug should be considered.  
  
Whenever possible, the CTCAE, Version 4.03, should be used for assessing the severity of AEs 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-4_QuickReference_8.5x11.pdf ).   
For AEs that are not adequately addressed in the NCI CTCAE, the standard severity grading scale 
may be used ( Table  6.3.1 ).  
  
  
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma  
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.   
  
  
78  
J1798/Version 5.0/May 21, [ADDRESS_376928] Adverse Event Severity Scoring System  
1  Mild:  Aware of sign or symptom, but easily tolerated.  
2  Moderate:  Discomfort enough to cause interference with usual 
activity.  
3  Severe:  Incapacitating with inability to work or do usual 
activity.  
4  Life-Threatening   Refers to an event in which the patient was, in the view 
of the Investigator, at risk of death at the time of the 
event. (This category is not to be used for an event that 
hypothetically might have caused death if it were more 
severe.)  
5  Fatal:  Event resulted in death.  
  
It will be left to the Investigator’s clinical judgment to determine whether an AE is related and of 
sufficient severity to require the patient’s removal from treatment or from the study.   
  
A patient may also voluntarily with draw from treatment due to what he/she perceives as an 
intolerable AE. If either of these situations arises, the patient should be strongly encouraged to 
undergo an end -of-study assessment and be under medical supervision until symptoms cease or the 
condit ion becomes stable.  
  
6.4 Serious Adverse Event Reporting Procedures  
  : 
  
  
79  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
SAEs will be collected and recorded throughout the study period, from the first dose of the 
investigational agent through [ADDRESS_376929] dose of study drug or end of the study (if 
thought to be related to study drug), or 30 days after the initiati on of a new anticancer therapy, 
whichever is earlier.    
  
All SAEs, regardless of causality to study drug and/or administration device, will be 
reported  
within [ADDRESS_376930]’s condition. All 
SAE(s) will be followed until:  
• Resolution  
• The condition stabilizes  
• The event is otherwise explained  
• The subject is lost to follow -up  
• Death  
  
As soon as relevant information is available, a follow -up SAE report will be submitted to the IND 
Sponsor, BMS, and Syndax.  
  
For all deaths, available autopsy reports and relevant medical reports should be provided to the 
IND Sponsor, Syndax and  BMS or their representative. If a patient is permanently withdrawn from 
the study because of an SAE, this information must be included in the initial or follow -up Serious 
Adverse Event Report Form as well as the EOT eCRF.   
  promptly  to  the  IND  sponsor      Syndax  
 and BMS  
  
  
80  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
The Investigator should notif y the IRB or EC of SAEs occurring at the site and other AE reports 
received from Syndax and BMS, in accordance with local procedures and statutes.  
  
6.5 Pregnancy and Lactation Reporting Procedures  
  
Although pregnancy and lactation are not considered AE s, it is the responsibility of Investigators 
or their designees to report any pregnancy or lactation in a patient (spontaneously reported to them) 
that occurs during the study or within [ADDRESS_376931] be followed to the completion/termination of the pregnancy.   
  
Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidi form mole, blighted 
ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as SAEs 
(Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must 
also be reported.  
  
Such events must be rep orted within 24 hours to the Sponsor either by [CONTACT_26365].   
  
6.6 Reporting of Overdose to the Sponsor  
  
6.6.1 Entinostat Overdose   
  
No information on the treatment of overdose of entinostat is currently available. Entinostat 
overdoses are defined as a single dose greater than 15 mg. This overdose will not be considered an 
SAE unless the outcome of the overdose meets seriousness criteri a as defined in Section 6.2.4  In 
the event of an entinostat overdose, the Sponsor should be immediately notified. The patient should 
be carefully monitored for potential adverse reactions and symptomatic treatment instituted as per 
institutional standards of care.   
  
6.6.2 Nivolumab Overdose  
  
A nivolumab overdose is considered an SAE. No specific information is available on the treatment 
of overdose of nivolumab. In the event of overdose, the patient should be observed closely for signs 
of toxicity. Appropriate supportive treatment should be pr ovided if clinically indicated.  
  
  
81  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
6.[ADDRESS_376932] continue to follow all SAEs and non -serious AEs considered to be reasonably 
or possibly related to study drug either until resolution or the Investigator assesses t hem as chronic 
or stable. This follow -up may extend after the end of the study.  
  
6.8 Reconciliation of SAEs  
  
The Principal Investigator (or designee) will reconcile the clinical database SAE cases (case level 
only) transmitted to the IND sponsor and BM S Global Pharmacovigilance  
. Frequency of reconciliation should be approximately every [ADDRESS_376933] 
from the Investigator, the reconciliation report. Requests for reconc iliation should be sent to 
 and . The data elements listed on the BMS  
GPVE reconciliation report will be used for case identification purposes. If the sponsor determines 
a case was not transmitted to the IND sponsor and/or BMS GVPE, the case should be s ent 
immediately to the IND sponsor and BMS.  
  
  
6.9 Safety Reporting to Health Authorities, Ethics Committees/Institutional Review Boards  
and Investigators  
  
The Sponsor will send appropriate safety notifications to Health Authorities in accordance with 
applicable laws and regulations.  
  
The Investigator must comply with any applicable site -specific institutional requirements related 
to the reporting of SAEs i nvolving his/her patients to the EC/IRB that approved the trial.  
  
In accordance with local regulations, the IND Sponsor or designee will notify investigators of all 
SAEs that are unexpected (i.e., not previously described in the IB), and related to the s tudy drugs. 
This notification will be in the form of an expedited safety report (ESR) that is to be faxed to the 
investigators and the study coordinators. Upon receiving such notices, the investigator must review 
and retain the notice with the IB and where  required by [CONTACT_427], the investigator will 
  
  
82  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
submit the ESR to the appropriate IRB. The investigator and IRB will determine if the informed 
consent requires revision. The investigator should also comply with the IRB procedures for 
reporting any ot her safety information.  
  
6.10 Food and Drug Administration (FDA) Reporting  
  
All reporting to the FDA will be completed by [CONTACT_9533].  
  
7 Calendar -Day Telephone or Fax Report:  
  
The IND Sponsor is required to notify the FDA of any fatal or life -threatening adverse event that 
is unexpected and assessed by [CONTACT_38241].  
Such reports are to be telephoned or faxed (301 -796-9849) to the FDA within [ADDRESS_376934] learning of the event. Follow -up information will be submitted to the FDA as soon as relevant 
information is available.   
  
10 Calendar -Day Written Report:    
  
The IND Sponsor is required to notify the FDA of any SAE that is unexpected and related to the 
investigational agent in a written IND Safety Report.    
  
Written IND Safety Reports should include an Analysis of Similar Events in accordance with 
regulation 21 CFR § 312.32.  All safety reports previously filed with the IND concerning similar 
events should be included in the analysis.  The new report should contain comments on the 
significance of the new event in light of the previous, similar reports.   
   
Follow-up information will be submitted to the FDA as soon as relevant information is available.  
  
IND Annual Reports:  
  
In accordance with the regulation 21 CFR § 312.33, the IND Sponsor shall within [ADDRESS_376935] submit a brief report of the adverse events and 
progress of the investigation.  Please refer to Code of Federal Re gulations, 21 CFR § 312.33 for a 
  
  
83  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
list of the elements required for the annual report.  All IND annual reports will be submitted to the 
FDA by [CONTACT_9533].  
  
6.[ADDRESS_376936] be noted on 
the eCRF.  
  
6.12 Safety Monitoring  
  
The safety and tolera bility of the investigational treatments will be monitored throughout the course 
of the study by [CONTACT_308068](s).  
The safety and tolerability data that will be reviewed will include, but are not limited to: AEs, 
unacc eptable toxicities, laboratory test results, and patient discontinuations. Additionally, the 
development of SAEs will be assessed by [CONTACT_308069](s) on a continuous 
basis. ( NOTE : all SAEs must be reported to the IND Sponsor, Syndax and B MS or designee within 
24 hours of discovery or notification of the event [ Section 6.4 ].)  
  
No formal safety stoppi[INVESTIGATOR_178878]. However, if any significant safety 
issues arise, a decision to modify or terminate the study will be made by [CONTACT_308070].  
  
  
7. PHARMACEUTICAL INFORMATION  
  
A list of the adverse events and potential risks associated with the investigational agents 
administered in this study can be found in Section 6.1 . Additiona l drug information can be found 
in the investigational agent’s Investigator Brochure.  
  
  
84  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
   
  
  
  
   
        
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
      
  
  
  
85  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
   
  
  
  
  
    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
   
  
  
86  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 
  
    
  
  
   
  
  
  
  
7.2  Nivolumab (NSC #748726)  
  
  
88  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
   
    
  
    
  
    
  
  
  
  
  
  
  
   
  
    
    
  
    
  
  
  
  
    
  
  
  
  
  
  
   
  
  
  
  
  
  
  
89  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 
  
8.[ADDRESS_376937] – Solid Tumors (RECIST 1.1)  
  
Although the clinical benefit of these drugs has not yet been established, the intent of offering this 
treatment is to provide a possible therapeutic benefit, and thus the subjects will be carefully 
monitored for tumor response and symptom relief in additi on to safety and tolerability. Subjects 
will be assessed by [CONTACT_308071] 
(Section 10 ).    
  
Response and progression will be evaluated in this study using the new international criteria 
propos ed by [CONTACT_459] (RECIST) guideline 
(version 1.1) [123]. Changes in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used  in the RECIST 
criteria.  
  
In addition, if a formal reading for RECIST measurements is performed, but the results are not 
available prior to the scheduled start of the next cycle, treatment should continue based upon 
review of the routine/clinical radiolo gist report of the status of disease (e.g., response, stability or 
progression).  In the event that a RECIST re -read would have changed the treatment decision for 
the subject, if known prior, the IND Sponsor/designee should be consulted and course of actio n   
  
  
  
  
   
  
  
  
  
  
  
  
[ADDRESS_376938]  
  
  
90  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
clearly documented in the medical record.  If it is in the best interests of the subject to continue on 
study, this is permissible.  These cases will be reviewed in detail at the time of study analyses.  
  
  
8.2 Definitions  
  
Evaluable for toxicity:  All patients will be included in the toxicity summaries, from the time of 
their first treatment with study drug.  
  
Evaluable for objective response :  All patients must be accounted for in the summary of objective 
response.  To formally classify a patient as RECIST -evaluable, only those patients who have 
measurable disease present at baseline (one of the eligibility criteria, Section 3.1 ) and start 
treatment (received at least one dose of entinostat) will be considered evaluable. These patients 
will have their  response classified according to the definitions stated below ( NOTE :  Subjects who 
exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)  
  
8.2.1 Disease Parameters  
  
Measurable disease:  Measurable lesions are defined as those that can be accurately measured in  
 
be recorded in millimeters (or decimal fractions of centimeters).  
  
NOTE : Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable. In most cases, in the event of post -radiation disease progression, 
previously irradiated lesions may be considered measurable lesions. Otherwise,  these lesions 
should be considered non -measurable.    
  
Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a lymph node 
must be ≥15 mm (≥1.5 cm) in short axis when assessed by [CONTACT_3610] (CT scan slice thickness 
recommended to b e no greater than 5 mm [0.5 cm]).  At baseline and in follow -up, only the short 
axis will be measured and followed.  
  
Non-measurable disease:  All other lesions (or sites of disease), including small lesions (longest  

  
  
91  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 
axis), are considered non -measurabl e disease.  Bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and 
abdominal masses (not followed by [CONTACT_462]), are considered as non -measurable.  
  
NOTE :  Cystic lesio ns that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non -measurable) since they are, by 
[CONTACT_108], simple cysts.  
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if 
they meet the definition of measurability described above. However, if non -cystic lesions are 
present in the same subject, these are preferred for selection as target lesions.  
  
Target lesions :  All measurable l esions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline.  Target lesions should be selected on the basis of their size (lesion s with the 
longest diameter), be representative of all involved organs, but in addition should be those that 
lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducib le measurement in which circumstance the next 
largest lesion which can be measured reproducibly should be selected.  A sum of the diameters 
(longest for non -nodal lesions, short axis for nodal lesions) for all target lesions will be calculated 
and reported  as the baseline sum diameters.  If lymph nodes are to be included in the sum, then 
only the short axis is added into the sum. A sum of the longest diameter (LD) for all target lesions 
will be calculated and reported as the baseline sum LD. The baseline su m LD will be used as 
reference by [CONTACT_14218].  
  
Non-target lesions :  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non -target le sions and should also be recorded 
at baseline.  Measurements of these lesions are not required, but the presence, absence, or in rare 
cases unequivocal progression of each should be noted throughout follow -up.  
  
8.2.2 Methods for Evaluation of Measurable Disease  
  
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 

  
  
92  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
never m ore than [ADDRESS_376939] 1.1 using radiographic scans every 8 weeks±7 days.  
  
The same method of assessment and the same technique should be used to characterize each 
identified and  reported lesion at baseline and during follow -up. Imaging -based evaluation is 
preferred to evaluation by [CONTACT_460](s) being followed cannot be 
imaged but are assessable by [CONTACT_461].  
  
Clinical lesions:  Clinical lesions will only be considered measurable when they are superficial  
 
calipers (e.g., skin nodules).  In the case of skin lesions, documentation by [CONTACT_6775], 
including a ruler to estimate the size of the lesion, is recommended.   
Chest x -ray:  Lesions o n chest x -ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776].  However, CT is preferable.   
  
Conventional CT and MRI :  This guideline has defined measurability of lesions on CT scan based 
on the assumptio n that CT slice thickness is 5 mm (0.5 cm) or less.  If CT scans have slice thickness 
greater than 5 mm (0.5 cm), the minimum size for a measurable lesion should be twice the slice 
thickness.  MRI is also acceptable in certain situations (e.g., for body sc ans).    
  
MRI has excellent contrast, spatial, and temporal resolution; however, there are many image 
acquisition variables involved in MRI, which greatly impact image quality, lesion conspi[INVESTIGATOR_3934], and 
measurement.  As with CT, if an MRI is performed, the technical specifications of the scanning 
sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, 
as with CT, the modality used at follow -up should be the same as was used at baseline and the 
lesions should be me asured/assessed on the same pulse sequence.    
  
PET-CT:  At present, the low dose or attenuation correction CT portion of a combined PET -CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if the 
site can document  that the CT performed as part of a PET -CT is of identical diagnostic quality to 
a diagnostic CT (with IV and oral contrast), then the CT portion of the PET -CT can be used for 
RECIST measurements and can be used interchangeably with conventional CT in accu rately 
measuring cancer lesions over time.  Note, however, that the PET portion of the CT introduces 

  
  
93  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
additional data which may bias an investigator if it is not routinely or serially performed.  Further, 
if the subject is allergic to contrast dye, the case  should be discussed with the IND Sponsor.    
  
Ultrasound :  Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  If new lesions are identified by [CONTACT_12153], 
confirmation by [CONTACT_12154].  If there is concern about radiation exposure at CT, MRI 
may be used instead of CT in selected instances.  
  
Endoscopy, Laparoscopy :  The utilization of these techniques for objective tumor evaluation is not 
advised.    
  
Tumor markers (CA 19 -9):  Tumor markers alone cannot be used to assess response.  If markers 
are initially above the upper normal limit, they must normalize for a subject to be considered in 
complete clinical response.    
  
Cytology : The cytological confirmation of the neoplastic  origin of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or stable disease 
is mandatory to differentiate between response or stable disease (an effusion may be a side effect 
of the treatment) and progressive disease.  
  
FDG -PET: While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in assessment 
of progression (particularly possible 'new' disease ).  New lesions on the basis of FDG -PET imaging 
can be identified according to the following algorithm:   
• Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD based 
on a new lesion.  
• No FDG -PET at baseline and a positive FDG -PET at follow -up:  If the positive FDG -PET at 
follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD.  If the positive 
FDG -PET at follow -up is not confirmed as a new site of disease on CT, additional follow -up 
CT  scans are needed to det ermine if there is truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG -PET scan).  If the positive FDG -PET 
at follow -up corresponds to a pre -existing site of disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.  
  
  
94  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy in cases 
where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use 
of FDG -PET in thi s circumstance should be prospectively described in the protocol and 
supported by [CONTACT_4623] -specific medical literature for the indication.  However, it must be 
acknowledged that both approaches may lead to false positive CR due to limitations of 
FDGPET and biopsy resolution/sensitivity.  
  
NOTE:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image.  
  
8.3 Response Criteria  
  
8.3.1 Evaluation of Target  Lesions  
  
Complete Response (CR) : Disappearance of all target lesions determined by [CONTACT_308072] 4 weeks apart. Any pathological lymph nodes (whether target 
or non -target) must have reduction in short axis to <10 mm ( <1 cm). There can be no appearance 
of new lesions.  
  
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of target lesions, taking 
as reference the baseline sum diameters.  
  
Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest 
on study).  In addition to the relative increase of 20%, the sum must also demon strate an absolute 
increase of at least 5 mm (0.5 cm).  ( NOTE:  the appearance of one or more new lesions is also 
considered progressions).  
  
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, ta king as reference the smallest sum diameters while on study.  
  
8.3.2 Evaluation of Non -Target Lesions  
  
  
  
95  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Complete Response (CR ): Disappearance of all non -target lesions and normalization of tumor 
marker level.  All lymph nodes must be non -pathological in size (<10 mm [<1 cm] short axis). 
NOTE :  If tumor markers are initially above the upper normal limit, they must normalize for a 
subject to be considered in complete clinical response.  
  
Non-CR/Non -PD: Persistence of one or more non -target lesion(s) and/or  maintenance of tumor 
marker level above the normal limits.  
  
Progressive Disease (PD) :  Appearance of one or more new lesions and/or unequivocal progression 
of existing non -target lesions. Unequivocal progression should not normally trump target lesion 
status.  It must be representative of overall disease status change, not a single lesion increase.  
  
Although a clear progression of “non -target” lesions only is exceptional, the opi[INVESTIGATOR_62484], and t he progression status should be confirmed at 
a later time by [CONTACT_463] (or PI).  
  
8.3.[ADDRESS_376940] response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).    
  
The subject's be st response assignment will depend on the achievement of both measurement and 
confirmation criteria ( Table 8.3.1 ).  
  
  
  
  
Table 8.3.1 For Subjects with Measurable Disease (e.g., Target Disease)  
  
  
Target  
Lesions  
    
Non-Target  
Lesions    
New  
Lesions    
Overall  
Response  Best  Overall  Response  when  
Confirmation is Required1  
CR  CR  No  CR  >4 wks confirmation  
  
  
96  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
CR  Non-CR/Non -PD  No  PR  
>4 wks confirmation  CR  Not evaluated  No  PR  
PR  Non-CR/Non - 
PD/not evaluated  No  PR  
SD  Non-CR/Non - 
PD/not evaluated  No  SD  Documented at least once >4 wks. from 
baseline  
PD  Any  Yes or No  PD*  
no prior SD, PR or CR  Any  PD**  Yes or No  PD*  
Any  Any  Yes  PD  
  
*A minority of subjects treated with immunotherapy may derive clinical benefit either delayed 
responses, stable disease, or increased overall survival despi[INVESTIGATOR_308023].    
  
Subjects may be permitted to co ntinue treatment beyond initial RECIST 1.1 -defined PD (see 
Section 4.9 ). In these cases, a radiological assessment will be repeated [ADDRESS_376941] criteria.    
  
** In exceptional circumstances,  unequivocal progression in non -target lesions may be accepted 
as disease progression.  
  
NOTE:  Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time shou ld be reported as “symptomatic 
deterioration;” (e.g., weight loss >10% of baseline body weight; worsening of tumor -related 
symptoms, decline in performance status >1 left on ECOG scale) after discussion with IND 
Sponsor. .Every effort should be made to doc ument the objective progression even after 
discontinuation of Treatment.  
  
8.3.[ADDRESS_376942] 1.1.  
  
8.3.5 Duration of Response  
  
  
  
99  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES  
  
9.1 Overview  
  
The major hypothesis of our correlative studies are that:  
1) Treatment with entinostat will result in changes in TME enhancing T cell effectors and/or 
reducing suppressive ability of CD4+FoxP3+ T regulatory cells and MDCSs in the tumors.  
2) Immunologic changes  in biopsy specimens will correlate with subsequent clinical response 
to anti -PD-1/PD -L1 therapy.  
  
Explorative correlative studies will be performed on biopsy specimens (pre - and post - entinostat 
treatment and approximately after 6 weeks from Cycle 1 da y 1) and blood samples.   
  
Mandatory research bloods and tumor biopsies will be obtained at baseline (day -14), after two 
weeks of entinostat lead in period (on approximately day [ADDRESS_376943] entinostat 
administration), and approximately after 6 week s from Cycle 1 day 1 visit. (see Study Calendar, 
Section 10 ). Biopsies at progression are optional.    
  
These three mandatory biopsies will provide valuable information regarding the mechanism of 
action of entinostat and the impact on the TME when PD1 inh ibition is added in, as well as primary 
resistance mechanisms to the strategy.  
  
NOTE: All samples will be collected as outlined below, initially processed, and stored/bank until 
future analysis.    
  
9.[ADDRESS_376944] or image -guided research biopsy procedure. FNA and on -site 
cytopathologic evaluation, where appropriate, will be done for sample/site adequacy followed by 
  
  
100  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
core biopsies for collection of tissue for the research correlates out lined.  The biopsy site will be 
clearly documented in the records; baseline and each follow -up biopsy will preferentially be done 
in the same organ site.    
  
Approximately six (6) core biopsy specimens will be obtained with each biopsy as outlined; the 
cytopathology slide will also be retained and submitted, if performed. Up to three cores will be 
placed in formalin solution and paraffin embedded. The remaining biopsy specimens will be flash 
frozen in liquid nitrogen and then stored as fresh tissue at ≤ -70°C for extraction of DNA and RNA. 
The biopsy specimens will be stored and batch shipped at the latest at the conclusion of study 
enrollment.  
  
The study staff will be notified when a biopsy is taking place. If core biopsy is not possible, other 
methods m ay be approved in advance by [CONTACT_9533]/designee.  
  
If a subject discontinues the study prior to a planned follow -up biopsy, an attempt should be made 
to collect the next scheduled biopsy when the decision is made to discontinue and prior to initiati on 
of additional treatment, if possible.   
  
In the event that a subject cannot undergo a second biopsy for any reason, including refusal, or the 
baseline biopsy was unsuccessful or invaluable, the second and the third biopsies, as well as the 
optional biop sy at the time of progression, will not be required and the subject will continue to be 
treated per study protocol.  
  
NOTE:  Archival tumor specimens from previously collected samples will be obtained for 
correlative analysis, if available.  
Biopsy Instruc tions  
  
Acceptable biopsy sites are:  
• Percutaneous biopsy of deep sites with local anesthetic and/or sedation (with an expected risk 
of severe complications < 2%)  
• Cutaneous biopsy of palpable sites with local anesthetic and/or sedation with an expected risk 
of severe complications < 2%  
• No open surgical or laparoscopic procedures will be performed solely to obtain a biopsy for 
this protocol.  
  
  
101  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
Such biopsies can be safely performed as evidenced by [CONTACT_308073] [122, 123], as well as, in 
the prior experience of our PI [INVESTIGATOR_308024] [124], where, among 244 research tumor 
biopsies (18G needle) in liver (126), subcutaneous/chest wa ll/abdominal wall (36), intramuscular 
(18), lung and lymph nodes, there were 8 minor cases of bleeding, and one pneumothorax requiring 
48h hospi[INVESTIGATOR_059] (21). This evidence support that serial percutaneous core -needle biopsies can 
be obtained safely yiel ding material applicable for multiple translational applications.  
  
Considering the tumor histologies to be enrolled in this study are pancreatic cancer and 
cholangiocarcinoma, biopsies will probably be of liver. In our institution, the expected 
complicat ion rate of percutaneous liver biopsy similar to those that will be done for this trial is less 
than 1 %. Risks of the procedure include, but are not limited to, bleeding, infection, pain, and 
scarring.  
  
9.2.2 Blood Samples  
  
Whole blood for PBMCs (up t o 180cc) will be collected at the specified timepoints (See Section 
10). Detailed instructions for blood collection, processing, and storage are provided in the 
Laboratory Manual.   
  
Sera (up to 10 cc) and plasma (up to 20cc) will be collected at the spec ified timepoints (See Section 
10). Detailed instructions for blood collection, processing, and storage are provided in the 
Laboratory Manual.  
  
In the event that a subject cannot have all blood samples or volume needed at a single visit, the 
samples and/o r remaining samples should be collected at the next possible visit.   
  
9.2.[ADDRESS_376945] by [CONTACT_308074]. The protocol scientific investigator(s) analyzing the samples will be 
blinded as to the direct subject identifiers.    
  
  
  
102  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
A Laboratory Manual will be provided for specific handling and processing instructions; this 
document will be disseminated with the clinical protoco l and is also available to investigators on 
request from the Coordinating Center.  
  
After shippi[INVESTIGATOR_007], samples, and associated data, will be stored at Johns Hopkins unless the subject 
withdraws consent.  
  
9.3 Methods  
  
9.3.1 Immunohistochemistry (IHC) and Gene Array Analyses  
  
The density of CD8+ Teffs, PD -1+, FoxP3+ Tregs, and the number of MDSCs will be evaluated by 
[CONTACT_308075]. Human PD -L1 IHC staining of paraffin embedded tumor specimens will 
be done usin g the Dako Catalyzed Signal Amplification system [126]. The density of cells will be 
determined at the junction between tumor tissue and non -tumor tissue (invasive front) and within 
the tumor (TILs). The densities will be reported as positive cells / mm2 of tissue using digital 
analysis. Each slide will be digitally scanned at 20X magnification and areas to be analyzed will 
be indicated using Aperio software.  PD -L1 expression is considered positive if membranous 
staining is present in more than 5% of the n eoplastic cells [127]. In addition, immune aggregates 
will be microdissected and evaluated for immune signatures using gene array analyses.  These 
studies will be conducted as previously described [128].  
  
9.3.2 Next Generation Sequencing (NGS)  
  
Tumor s pecific somatic mutations will be identified by [CONTACT_28760] -exome sequencing (WES)  using  
DNA isolated from tumor tissue, along with subject -matched normal lymphocytes. Genomic DNA 
from tissue and lymphocyte sample will be sonicated to a modal size of [ADDRESS_376946] to massively parallel sequence -by-synthesis 
100x100 bp paired end sequencing on an Illumina HiSeq 2000 at a minimal depth of 75x average 
coverage. The resulting reads wi ll be aligned to the genome using bowtie2 and variants will be 
called on each sample compared to the human reference using the GATK software. Somatic 
variants will be identified using the strelka software.  
  
  
103  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
The T cell repertoire in TILs will be evaluated  in tumor specimens using Adaptive 
Biotechnologies’ next -generation sequencing -based approach.   
  
9.3.3 HLA -Binding Prediction Algorithms and Elispot Assays  
  
Quantification of tumor neoantigen -specific CD8+ T cell levels in PBL:  Each of the somatic 
missense mutations identified by [CONTACT_308076] I -binding 
neoepi[INVESTIGATOR_308025].  19mer peptides will be synthesized spanning 
each mutation predicted to generate a neoeptiope; and used in IFN ELISPOT a ssays to measure 
neoepi[INVESTIGATOR_9230] -specific CD8+ T cell levels in PBL.  
  
9.3.4 MDSC Analysis  
  
Levels of granulocytic and monocytic MDSCs in peripheral blood will be evaluated by 6 -color 
fluorescence -activated cell sorting (FACS) using monoclonal antibodies specific to CD11b, CD14, 
CD15, CD33, HLA -DR and the IL -4 receptor.  
  
10. STUDY CALENDAR  
  
Notations/reminders for all calendars :    
• Baselines assessments are to be conducted within 28 days of registration unless otherwise noted. 
 Correlative blood and tissue sample participation is mandatory.   
• Additional tests may be performed at the discretio n of the treating investigator as per routine 
practice, or as otherwise clinically indicated.  
The schedule should be followed as closely as is realistically possible; the schedule may be 
modified due to problems such as scheduling delays or conflicts (e.g ., clinic closure, vacations, 
etc.) with the guidance of the IND Sponsor/designee, as appropriate, and will not be reportable as 
a deviation unless the endpoints of the study are affected.  
  
*     Required ≤ [ADDRESS_376947] dose of entinostat   
**   Required assessment windows during combination treatment for each cycle as noted (e.g.,  
Days 1 and 15 is 3 days, weekly is ±1 day).  Assessments on Days 1 and 15 should be  
completed/reviewed prior to planned nivolumab administration.  
  
  
104  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
***  After 4 m onths, nivolumab will be given at a dose of 480 mg fixed dose every 4 weeks  
(maintenance phase). Therapy may continue with entinostat 5 mg weekly plus nivolumab  480 
mg every 4 weeks, until intolerance or progression.  
 Patients will be assessed in clinic  on D1 of every cycle, and will be contact[CONTACT_308077], 
on the weeks entinostat alone is self -administered at home.   
  
# Required ≤ [ADDRESS_376948] dose of entinostat  
  
NOTE : All timeframes noted after the lead -in phase refer to duration  on combination treatment 
(e.g., first -restaging should occur after 8 weeks of initiation of combination treatment of entinostat 
and nivolumab.)   
  
  
    
 
   
 
  
9. Thyroid function will be assessed by [CONTACT_118064] (Thyroid Stimulating Hormone) at baseline and prior to each dose of nivolumab.  If 
abnormal, Free T3 (triiodothyronine) and T4 (thyroxine) should be assessed.  
10. The following should be assessed at baseline: Hepatitis  B surface antigen (HBV sAg) and Hepatitis C antibody (HCV Ab) or 
Hepatitis C RNA (HCV RNA).  
11. An ECG is required during screening (prior to starting study treatment), as well as at any other time point when clinically i ndicated. 
All [ADDRESS_376949] 5 minutes.   
12. Bilirubin, blood, g lucose, ketones, pH, protein, specific gravity, color and appearance.  Microscopy should be used as appropriate 
to investigate white blood cells and use the high power field for red blood cells  
13. For WOCBP (women of childbearing potential) only.  A serum or  urine pregnancy testing is required prior to study 
enrollment/registration, ≤[ADDRESS_376950] dose of entinostat and <[ADDRESS_376951] within 72 hours prior to receiv ing 
retreatment with study medication. NOTE: If a patient has a positive or indeterminate serum or urine pregnancy test, then an 
ultrasound must be done to rule out pregnancy to enroll on trial. A serum B -HCG value of <[ADDRESS_376952]/abdomen/pelvis (CT preferred, abdominal/pelvis MRI will be performed for patients with CT contr ast 
allergy) and any other imaging required per RECIST for the particular subject are required at baseline. A baseline bone scan or 
PET/CT could be required to assess bone disease in patients with suspected or known bone metastases.  A baseline brain CT sc an 
or MRI is requested in patients with suspected or known brain metastases.   Repeat same modality(ies) in follow -up to follow known 
site(s) of disease, with other assessments as clinically indicated if one has not been done within the past 6 weeks.  .  
15. Entinostat is to be self -administered by [CONTACT_178899].   
16. Patients will receive entinostat 5 mg oral once a week plus nivolumab 240 mg every two weeks for approximately four months. 
After 4 months (16 weeks), nivolumab will be given at a dose of 480 mg  fixed dose every 4 weeks. Therapy may continue with 
entinostat 5 mg weekly plus nivolumab 480 mg every 4 weeks, until intolerance or progression.  
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Me  tastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator  :   [INVESTIGATOR_307987], M.D.    
  
   
 
 17. Blood for serum and plasma samples will be collected at baseline (D -14), after entinostat lead in (on appro ximately day 14 (D -1) 
of entinostat therapy), on week 6, prior to dosing on C2D15, and at the time of the EOT visit. Detailed instructions for bloo d 
collection, processing, and storage are provided in the Laboratory Manual.  
18. Mandatory fresh tissue samples will be collected at D -14 and after entinostat lead -in (on approximately day 14 (D -1) of entinostat 
therapy prior to dosing on C1D1) and on week 6, prior to dosing on C2D15. A ±3 day window applies to both time points. All  
93  
J1798/Version 5.0/May 21, 20 20  
 
  
samples are collected pre -dose on treatment days). Approximately six (6) core biopsy specimens will be obtained with each biopsy  
as outlined; the cytopathology slide will also be retained and submitted, if performed (See Section 9.2.1 ) All 
correlative blo od/tissue studies should be performed on the same day.    
NOTE:  If applicable, the daily dose of entinostat may occur prior to hematology/chemistry tests and these laboratory tests may be 
drawn at the same time as the correlative blood samples.  
19. A third mandatory biopsy will be performed at week 6 from Cycle 1, Day1. A window of +14 days applies to this time point  
20. An optional biopsy will be performed at the time of disease progression.  
21. Archival tumor specimens from previously collected samples w ill be obtained for correlative analysis, if available.  
22. Weekly assessments for toxicity/adverse events may occur by [CONTACT_308078]. Additionally , 
assessments are to continue for [ADDRESS_376953] dose of nivolumab  (at intervals <21 days) or to resolution of drug -related AEs 
to ≤ Grade 1, whichever occurs later. SAEs that occur within [ADDRESS_376954] treatment or before initiation of a new ant ineoplastic 
treatment should also be followed and recorded.  These ma y occur by [CONTACT_308079]; 
however, an in -person clinic visit may be needed to confirm event resolution and/or to effectively evaluate possible immune -related 
events.  Subjects must be told of follow -up requireme nts at study entry.   
23. Subjects who complete or discontinue from treatment because of progression disease will be followed (by [CONTACT_61529]) every  
three months (+/ - 2 weeks) after completion of the EOT visit for up to 2 years or study closure to monitor o verall survival. 
Information of other cancer therapi[INVESTIGATOR_308026].   
For subjects who discontinue treatment for reasons other than tumor progression, will be contact[INVESTIGATOR_530] (by [CONTACT_61529]) every three 
months (+/ - 2 weeks) after completion of the EOT for up to 2 years or study closure to monitor overall survival, and information 
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Me  tastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator  :   [INVESTIGATOR_307987], M.D.    
  
   
 
 about disease status will be also collected if possible (i.e. radiological imaging and/or tumor markers) until documented tu mor 
progression.  
  
NOTE : For evaluation of PFS, all subjects who discontinue study drug administration prior to [ADDRESS_376955] restaging 
scans/imaging within a 7 day window of the 6 month time point from the date of initiation of combination treatment  
94  
J1798/Version 5.0/May 21, 2020   
  
  
111  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
11. DATA REPORTING / REGULATORY REQUIREMENTS  
  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 6  
(Adverse Events: List and Reporting Requirements).  
  
11.1 Data Management  
  
All information will be collected on study -specific case report forms (CRFs) by [CONTACT_464]. These 
data will be reviewed for completeness and accuracy by [CONTACT_978].   
  
CRFs will be used to capture study results and data. The study coo rdinator or other authorized 
study personnel will transcribe data from source documents onto eCRFs. Before or between visits, 
the IND Sponsor,, Syndax and BMS or designee may request copi[INVESTIGATOR_308027]. Once the CRFs are comp lete and source -verified, the investigator must sign and 
date all required pages, verifying the accuracy of all data contained within the CRF. Training will 
be provided on proper completion of CRFs.  
  
11.[ADDRESS_376956] Anonymity  
  
All information about the nature of the proposed investigation (with the exception of information 
required by [CONTACT_61475], the subject or the appropriate regulatory 
authority) must be kept in confidence by [CONTACT_308080].  
  
The anonymity of participating subjects must be maintained. Subjects will be identified by [CONTACT_308081], Syndax and BMS, study monitor, regulato ry agencies, or central 
laboratories/reviewers. Documents that identify the subject (e.g., the signed ICF) must be 
maintained in strict confidence by [CONTACT_093], except to the extent necessary to allow auditing 
by [CONTACT_61476] , the study monitor, IND Sponsor or their representative.  
  
11.3 Protocol Compliance  
  
  
  
112  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Substantive changes in the protocol include changes that affect the safety of subjects or changes 
that alter the scope of the investigation, the scientific quality of the study, the experimental design, 
dosages, assessment variable(s), the number of subjects treated or the subject selection criteria.   
  
A protocol amendment must receive IRB approval before implementation. In parallel with the IRB 
approval process, the protocol amendment will be submitted to the appropriate regulatory authority 
as an amendment to the regulatory submission under which the study is being conducted. If a 
protocol amendment requires changes in the ICF, the revised ICF and protocol prepared b y the 
investigator must also be approved by [CONTACT_9533], Syndax/BMS, and the IRB before 
implementation.  
  
Emergency departures from the protocol that eliminate an apparent immediate hazard to a 
particular subject and that are deemed crucial for the safety and well -being of that subject may be 
instituted for that subject only. The investigator or the attending physician also will contact [CONTACT_308082]/or designee as soon as possible in the case of such a departure. These departures 
do not require preapproval by [CONTACT_1201]; however, the IRB and the IND Sponsor and/ or designee 
must be notified in writing as so on as possible after the departure has been made. In addition, the 
investigator will document in the subject’s CRF the reasons for the protocol deviation and the 
ensuing events.  
  
11.[ADDRESS_376957] weekly and will include the protocol PI, study coordinator(s), 
research nurse (s), and sub -investigators (as appropriate). During these meetings matters related to 
the following will be discussed: safety of protocol participants, validity and integrity of the data, 
enroll ment rate relative to expectation, characteristics of participants, retention of participants, 
adherence to protocol (potential or real protocol violations), data completeness, and progress of 
data for objectives.  
    
Quarterly teleconferences will be sch eduled to include the Investigator and Syndax and BMS 
representatives. During these meetings, the Investigator shall provide Syndax and BMS with study 
progress updates. The Investigator will provide a summary of key points from the weekly meetings 
with a f ocus on safety of the protocol participants, enrollment status, and progress of data for 
objectives. In addition, both Syndax and BMS will provide safety and applicable program updates 
to the Sponsor.  
  
  
113  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
11.5 Monitoring  
  
The SKCCC Compliance Monitoring P rogram will provide external monitoring for JHU -affiliated 
sites in accordance with SKCCC DSMP (Version 6.0, 02/21/2019).  The SMC Subcommittee will 
determine the level of patient safety risk and level/frequency of monitoring.   
  
[CONTACT_308097] wil l be holding the IND for this study. She will comply with all regulated 
reporting requirements to the FDA.  
  
12. STATISTICAL CONSIDERATIONS  
  
12.1 Overall Study Design  
  
This is an open -label, two -stage, phase 2 study evaluating the clinical activity an d safety of 
entinostat plus nivolumab. We will enroll two cohorts of patients: unresectable or metastatic 
cholangiocarcinoma (Cohort 1) and unresectable or metastatic pancreatic adenocarcinoma (Cohort 
2). Patients must have progressed (or were intolerant) to 1 or 2 prior chemotherapy regimens in the 
metastatic setting, or progression < 6 months from the completion of adjuvant chemotherapy.  
  
The primary objective of the trial is to determine whether the combination of entinostat plus 
nivolumab yields a cli nically compelling antitumor activity measured as objective response rate 
(ORR, assessed by [CONTACT_393] 1.1). Secondary endpoints include safety, progression -free survival 
(PFS), overall survival (OS), and immunologic correlates.   
  
The study is planned with 27 evaluable subjects per histology, based on a two -stage design that 
allows early termination for lack of efficacy.   
  
12.2 Sample Size and Accrual Rate   
  
Approximately 27 patients with unresectable or metastatic CCA and 27 pa tients with locally 
advanced or metastatic PDAC will be enrolled, with ORR as the primary endpoint. Enrollment 
will be carried out in 2 stages so that the study can terminate early if the combination of entinostat 
plus nivolumab is not sufficiently effecti ve.   
  
  
114  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
Simon’s two -stage, minimax, design will be employed in each cohort to test the null hypothesis 
that the true ORR is 5% or less (not considered clinically compelling for this combination). In the 
first stage, [ADDRESS_376958] 13 subjects, the study will be terminated for futility. 
Otherwise, 14 additional subjects will be accrued to target a total of 27 treated and response 
evaluable subjects. The null hypothesis will be rejected if 4 or more  responses are observed in 27 
subjects per each cohort.   
The probability of stoppi[INVESTIGATOR_308028] 51% if the true ORR is 5% or less. This 
design yields 80% power at a one -sided type I error rate of 5% when the true response rate is 20% 
The study may enroll [ADDRESS_376959] confidence interval.  
  
12.3.2 Analysis of Secondary Endpoints  
  
  
  
115  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
• OS is defined as the duration of time from start of study treatment to time of death. For 
subjects lost to follow -up or whose vital status is unknown, every effort will be made to 
determine the date such subjects were last known t o be alive. Such efforts may include phone 
calls, certified mail, and the checking of public records. Subjects who are alive or lost to 
follow -up as of the data analysis cutoff date will be right -censored. The censoring date will 
be determined from the dat e the subject was last known to be alive.  
  
• PFS is defined as the time from cycle 1, day [ADDRESS_376960] 
(version 1.1). Due to the exp ectation that some patients may experience delayed clinical 
responses to therapy, patients with disease progression by [CONTACT_308083] a [ADDRESS_376961] 1.1 and immune -related response criteria (irRC). Individuals will be 
censored at the date of the la st scan for PFS if no event occurs.  
  
Median time to event will be calculated and reported with confidence intervals.   
  
Analysis of PFS will be restricted to evaluable individuals who complete at least one dose of 
entinostat, while the analysis of OS will be performed on all evaluable patients.   
  
OS curves, OS medians with 95% CIs, and OS rates at 6, 12, 24 and 36 months with 95% CIs 
will be estimated using Kaplan -Meier methodology  
  
PFS curves, PFS medians with 95% CIs, and PFS rates at 6, 12 and 24 months with 95% CIs 
will be estimated using Kaplan -Meier methodology.  
  
• Duration of response (DOR) will be calculated for subjects who achieve a best overall 
response of CR or PR with entinostat in combination with nivolumab. For such subjects, 
  
  
116  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
duration of response is defined as the number of weeks from the start date of PR or CR 
(whichever response is recorded first) and sub sequently confirmed to the first date that 
recurrent or progressive disease or death is documented. In such cases, recurrent or 
progressive disease will be assessed relative to the smallest tumor measurements recorded 
since the start of study treatment. Th e primary analysis of duration of response will be based 
on the time point responses, best overall response, and PD status that are determined by [CONTACT_308084] -Meier method with 95% co nfidence 
intervals (CIs)  
  
• The safety analysis will be performed in all subjects who receive any amount of study drug. 
A baseline measurement and at least [ADDRESS_376962] 1 dose of study treatment m ay be required for inclusion in the analysis 
of a specific safety parameter (e.g., lab shifts from baseline).   
  
A complete list of all AE data will be provided along with an assessment of NCI CTCAE 
grade and relationship to study drug. The incidence of A Es will be tabulated by [CONTACT_308085] (e.g. grade 3 or higher, organ class, relationship to study drug).   
  
For analyses at the individual level, the highest grade and relationship to study drug will be 
assumed if multiple events have occurred.   
  
Toxicity will be tabulated by [CONTACT_308086]. 
Other safety data will be assessed in terms of physical examination, clinical chemistry, 
hematology, vital signs, and ECGs. Negative binomial regression and Cox proportional hazards 
models will be used to assess the rate of AE and time to first toxicity, respectively.  
  
12.3.3 Data & Safety Monitoring  
  
The PI [INVESTIGATOR_308029], and any endpoint problems that might be developi[INVESTIGATOR_007]. The 
Sidney Kimmel Comprehensive Cancer Center Clinical Research Review Committee and Safety 
Monitoring Committee are responsible for reviewing accrual and safety data for t his trial at least 
twice a year.  
  
  
117  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
12.3.4 Analysis of Exploratory Endpoints  
  
Exploratory correlative studies will be performed to investigate:  
▪ To measure the baseline levels of  immune markers including CD8+ T effector cells and 
CD4+FoxP3+ T regulatory  cells, PD -L1 expression and tumor infiltrating lymphocytes 
(TILs), major histocompatibility complex (MHC) class I and II expression, and natural killer 
(NK) cell receptors and ligands expression and correlate these variables with treatment 
response and to xicity.  
▪ To characterize changes in the immune markers described above after treatment  
▪ To identify gene expression changes in malignant tissue after therapy, and complete gene set 
analysis to elucidate affected pathways  
▪ To measure changes in circulating immune suppressor cells (MDSC, Treg) in peripheral 
blood by [CONTACT_308087].  
  
The overarching aim of these exploratory studies is to establish baseline levels and measure 
changes in immunological pathways after treatment. Little is known about baseline levels for these 
variables in Cholangiocarcinoma and Pancreatic Adenocarcinoma, let alone changes after 
treatment, and if the primary and secondary aims are successful, these investigations will establish 
a biological foundation on which to build in follow -up studies.   
  
Immunological variables will be examined in plots and summary statistics, to characterize 
distributions, identify outliers and other potential problems in the data.   Joint exploratory analysis 
will identify associations and potential interactions.   Varia bles may be transformed on the basis 
of these investigations, to reduce skewness, minimize the influence of outliers and/or to regularize 
relationships between predictors and response for better model fit. Exploratory analysis of the 
molecular markers, inc luding visualizations and statistical summaries such as hierarchical cluster 
analysis, heat maps, multidimensional scaling, and principle component analysis will offer 
important views of the structural characteristics of the expression data.    
  
Response will be described categorically, and associations between response and immunological 
variables will be characterized, in each cohort, using multivariate logistic regression models, with 
adjustment for clinical and pathological co -variates that may be assoc iated with response. 
Estimated effects will be reported with standard errors and confidence intervals.    
  
  
118  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
We will fit  empi[INVESTIGATOR_308030] [129] to identify genes for which expression is associated 
with response to treatment,  controlling type I er ror at an FDR of <10%. Gene set enrichment 
analysis [130, 131] will be applied to the results to identify immune pathways that are significantly 
altered after treatment.   
  
13. REFERENCES  
  
1. Kleeff J, Korc M, Apte M, et al. Pancreatic Cancer. Nat Rev Dis Primers. 2016;2:[ZIP_CODE]  
2. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab -paclitaxel plus 
gemcitabine. N Engl J Med.2015;369:1691 –1703.  
3. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl 
J Med. 20 11;364: 1817 –1825.  
4. Wang -Gillam A, Li CP, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and 
folinic acid in metastatic pancreatic cancer after previous gemcitabine -based therapy 
(NAPOLI -1): a global, randomised, open -label, Phase 3 trial. Lanc et. 2016;387:545 -557  
5. Oettle H, Riess H, Stieler JM et al. Second line oxaliplatin, folinic acid, and fluorouracil 
versus folinic acid and fluorouracil alone for gemcitabine -refractory pancreatic cancer: 
outcomes from the CONKO -003 trial. J CliN. Oncol. 20 14;32:2423 –2429.  
6. Gill S, Ko YJ, Cripps C, Beaudoin A, et al. PANCREOX: A Randomized Phase III Study 
of 5-Fluorouracil/Leucovorin With or Without Oxaliplatin for Second -Line Advanced 
Pancreatic Cancer in Patients Who Have Received Gemcitabine -Based Chemoth erapy. J 
Clin Oncol. 2016;Sep 12. pii: JCO685776. [Epub ahead of print].  
7. Ko, A.H., Progress in the treatment of metastatic pancreatic cancer and the search for next 
opportunities. J Clin Oncol, 2015;33:1779 -1786.  
8. Siegel RL, Miller KD, Jemal A. Cancer sta tistics, 2016. A cancer journal for clinicians: CA; 
2015.  
9. Ebata T, Ercolani G, Alvaro D, et al. Current Status on Cholangiocarcinoma and Gallbladder 
Cancer. Liver Cancer. 2016;6:[ADDRESS_376963] cancer. N Engl J Med 2010;362:1273 -1281.  
11. Blechacz B.  Cholangiocarcinoma: Current Knowledge and New Developments. Gut and 
Liver. 2017;11:13 -26.  
12. Danny N. Khalil DN,  Smith E , et al. The future of cancer treatment: immunomodulation, 
CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273 -90  
  
  
119  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
13. Phan, G. Q. et al. Cancer regression and autoimmunity induced by [CONTACT_28746] T lymphocyte 
associat ed antigen 4 blockade in patients with metastatic melanoma. Proc.Natl Acad Sci. 
[LOCATION_003]. 2003;100:8372 –8377.  
14. Parry, R. V. et al. CTLA ‑4 and PD ‑1 receptors inhibit T ‑cell activation by [CONTACT_308088]. Mol Cell Biol. 2005;25:9543 –9553.  
15. Okazaki, T. & Honjo  T. PD‑1 and PD‑1 ligands: from discovery to clinical application. Int.  
Immunol. 2007;19: 813 –824.  
16. Hodi, F. S. et al. Improved survival with ipi[INVESTIGATOR_8612]. 
N Engl J Me. 2010:363:711 –723.  
17. Robert C. et al. Nivolumab in pr eviously untreated melanoma without BRAF mutation. N 
Engl J Med. 2014:372: 320 –330.  
18. Larkin, J. et al. Combined nivolumab and ipi[INVESTIGATOR_222101]. N Engl J Med. 2015;373:23 –34.  
19. Brahmer, J. et al. Nivolumab versus docetaxel in a dvanced squamous -cell non -small -cell 
lung cancer. N Engl J Med. 2015;373:123 –134.  
20. Topalian, S. L. et al. Safety, activity, and immune correlates of anti ‑PD‑1 antibody in 
cancer. N Engl J Med. 2012;366:2443 –2454.  
21. Rizvi NA, Hellmann MD, Snyder A, et al. Ca ncer immunology. Mutational landscape 
determines sensitivity to PD -1 blockade in non -small cell lung cancer. Science. 
2015;348:124 –128.  
22. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA -4 
blockade in melanoma. N Engl J Me d. 2014;371:2189 –99.  
23. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature. 
2013;500:415 –421.  
24. Naboush A, Roman CA, Shapi[INVESTIGATOR_20116] I. Immune checkpoint inhibitors in malignancies with 
mismatch repair deficiency: a review of the stat e of the current knowledge. J Investig Med. 
2017 Jan 19. doi: 10.1136/jim -2016 -000342.   
25. Jones, P. A. & Baylin, S. B. The fundamental role of epi[INVESTIGATOR_308031]. Nat Rev 
Genet.2002;3:415 –428.  
26. Esteller, M. Epi[INVESTIGATOR_166102]. N Engl J Med. 2008 ;358:1148 –1159.  
  
  
120  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
27. Baylin SB. & Jones PA. A decade of exploring the cancer epi[INVESTIGATOR_307999] — biological and 
translational implications. Nat  Rev Cancer. 2011;11:726 –734.  
28. Dawson MA & Kouzarides T. Cancer epi[INVESTIGATOR_7009]: from mechanism to therapy. Cell. 
2012;150:12 –27.  
29. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epi[INVESTIGATOR_308032] --lessons from the past. Nat Rev Clin Oncol. 2013;10:256 -266.  
30. Doi A. et al. Differential methylation of tissue - and cancer -specific CpG island shores 
distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. 
Nat Genet. 2009;41:1350 –1353.  
31. Waddell N, Pajic M, Patch AM, et al. Whole geno mes redefine the mutational landscape of 
pancreatic cancer. Nature 2015;518:495 –501.  
32. Hashimoto, H., Vertino, P. M. & Cheng, X. Molecular coupling of DNA methylation and 
histone methylation. Epi[INVESTIGATOR_241188]. 2010;2:657 –669.  
33. Jiao Y, Pawlik TM, Anders RA, et al . Exome sequencing identifies frequent inactivating 
mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 
2013;45:1470 -1473.  
34. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. 
Nat Rev D rug Discov 2006;5:769 –84.  
35. Khan O, La Thangue NB.  HDAC inhibitors in cancer biology: Emerging mechanisms and 
clinical applications. Immunol Cell Biol 2012;90:85 –94.  
36. Kim K, Skora AD, Li Z, et al. Eradication of metastatic mouse cancers resistant to immune  
checkpoint blockade by [CONTACT_108694] -derived cells. Proc Natl Acad Sci U S A. 
2014;111:[ZIP_CODE] -[ZIP_CODE].  
37. Robert C. & Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer 
Res. 2012;116:87 –129.   
38. Popovic R & Licht JD. Emerging epi[INVESTIGATOR_308033]. 
Cancer Discov. 2012;2: 405 –413.  
39. Shen L, Ciesielski M, Ramakrishnan S,et al. Class I Histone Deacetylase Inhibitor 
Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapi[INVESTIGATOR_308034]. PLoS One. 2012;7: e30815.  
40. Sriraksa R, Limpaiboon T. Histone deacetylases and their inhibitors as potential therapeutic 
drugs for cholangiocarcinoma - cell line findings. Asian Pac J Cancer Prev. 
2013;14:25032508.  
  
  
121  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
41. Baradari V, Höpfner M, Hueth er A, et al. Histone deacetylase inhibitor MS -275 alone or 
combined with bortezomib or sorafenib exhibits strong antiproliferative action in human 
cholangiocarcinoma cells. World J Gastroenterol. 2007;13:4458 –4466.  
42. R Pi[INVESTIGATOR_45769], B Salumbides, M Zhao, et al. Pha se I study of the histone deacetylase inhibitor 
entinostat in combination with 13 -cis retinoic acid in patients with solid tumours. Br J 
Cancer. 2012;106:77 –84.  
43. Alexander Arlt & Heiner Schäfer. Investigational histone deacetylase inhibitors for treating 
pancreatic adenocarcinoma Expert opi[INVESTIGATOR_308035]. 2016;25:1251 –1254.   
44. Hessmann E, Johnsen SA, Siveke JT, et al. Epi[INVESTIGATOR_308036]: is 
there a therapeutic perspective on the horizon? Gut 2017;66:168 –179.  
45. Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic 
cancer: are there any promising clinical trials? World J Gastroenterol. 2013;19:1173 –1181.  
46. Jones SF, Bendell JC, Infante JR, et al. A phase I study of panobinostat in combination w ith 
gemcitabine in the treatment of solid tumors. Clin Adv Hematol Oncol. 2011;9:[ADDRESS_376964], et al. Phase 1 Results From a Study of Romidepsin in 
Combination With Gemcitabine in Patients With Advanced Solid Tumors. Cancer 
Investigation. 2012;30:6  
48. Richards DA, Boehm KA, Waterhouse DM, et al. Gemcitabine plus CI -994 offers no 
advantage over gemcitabine alone in the treatment of patients with advanced pancreatic 
cancer: results of a phase II randomized, double -blind, placebo -controlled, multicenter 
study. Ann Oncol. 2006;17:1096 –1102  
49. Kleeff, J. et al. Pancreatic cancer microenvironment. Int. J. Cancer. 2007;121:699 –705.  
50. Wang, L. M. et al. The prognostic role of desmoplastic stroma in pancreatic ductal 
adenocarcinoma. Oncotarget . 2016;7:4183 –4194.  
51. Amedei A, Niccolai E & Prisco D. Pancreatic cancer: role of the immune system in cancer 
progression and vaccine -based immunotherapy. Hum. Vaccin. Immunother. 2014;10:3354 – 
3368.  
52. Le DT. et al. Safety and survival with GVAX pancreas prime and Listeria 
monocytogenesexpressing mesothelin (CRS ‑207) boost vaccines for metastatic pancreatic 
cancer. J Clin Oncol. 2015;33:1325 –1333.  
53. Khaled, Y. S., Wright, K., Melcher, A. & Jayne, D. Anti ‑cancer effects of oncolytic viral 
therapy combined with photodynamic therapy in human pancreatic cancer cell lines. Lancet. 
2015;385, S56.  
  
  
122  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
54. Soares, K. C. et al. PD ‑1/PD‑L1 blockade together with vaccine therapy facilitates effector  
T‑cell infiltration int o pancreatic tumors. J. Immunother 2015;38:1 –11.  
55. Brahmer, J. R. et al. Safety and activity of anti ‑PD‑L1 antibody in patients with advanced 
cancer. N Engl J Med. 2012;366:2455 –2465.  
56. Feig C. et al. Targeting CXCL12 from FAP -expressing carcinoma -associated  fibroblasts 
synergizes with anti ‑PD‑L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci [LOCATION_003].  
2013;110:[ZIP_CODE] –[ZIP_CODE].  
57. Lutz, E. R. et al. Immunotherapy converts nonimmunogenic pancreatic tumors into 
immunogenic foci of immune regulation. Cancer Immuno l Res. 2014;2:616 –631.  
58. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic 
carcinoma in mice and humans. Science. 2011;331:1612 –1616.  
59. Beatty, G. L. et al. Exclusion of T cells from pancreatic carcinomas in mice is r egulated by 
[CONTACT_308089]6Clow F4/80+ extratumoral macrophages. Gastroenterology. 2015;149:201 –210.  
60. Silverman BR and Jiaqi Shi J. Alterations of Epi[INVESTIGATOR_308037]. Int J Mol Sci 2016;17:2138 -2145  
61. Jones PA & B aylin SB. The epi[INVESTIGATOR_308038]. Cell. 2007;128:683 –692.  
62. Baylin SB & Jones PA. A decade of exploring the cancer epi[INVESTIGATOR_307999] - biological and 
translational implications. Nat  Rev Cancer. 2011;11:726 –734.  
63. Witkiewicz AK, McMillan EA, Balaji U, et al. Whole -exome sequencing of pancreatic 
cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744 –6755.   
64. Ougolkov AV, Bilim VN,  Billadeau DD. Regulation of pancreatic tumor cell proliferation 
and chemoresistance by [CONTACT_308090] 2. 
Clin Cancer Res. 2008;14:6790 –6796.  
65. Sigalotti L, Fratta E, Coral S, et al. Epi[INVESTIGATOR_308039]. Pharmacol Ther. 2014;142:339 –350.  
66. Suleiman Y, Coppola D, Ziba di S, et al. Prognostic value of tumor -infiltrating lymphocytes 
(TILs) and expression of PD -L1 in cholangiocarcinoma.J Clin Oncol. 2015; (suppl 3; abstr 
294)  
  
  
123  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
67. Sabbatino F, Villani V, Yearley JH, et al. PD -L1 and HLA class I antigen expression and 
clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 
2016;22:470 –478.   
68. Gani F, Nagarajan N, Kim Y,et al.  Program Death 1 Immune Checkpo int and Tumor 
Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Ann 
Surg Oncol. 2016;23:2610 –2617.  
69. Tran E, Turcotte S, Gros A, et al. Cancer Immunotherapy Based on Mutation -Specific CD4+ 
T Cells in a Patient with Epi[INVESTIGATOR_308040]. Science. 2014;344:641 -645.  
70. Le DT, Uram JN, Wang H, et al. PD -1 blockade in tumors with mismatch -repair deficiency. 
N Engl J Med. 2015;372:2509 –2520.  
71. Bang YJ, Doi T, Braud FD, et al. Safety and efficacy of pembrolizumab (MK -3475) in 
patients (pts ) with advanced biliary tract cancer: interim results of KEYNOTE -028. Eur J 
Cancer. 2015;51:S112.  
72. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur 
frequently in intrahepatic cholangiocarcinomas and share hypermethylation  targets with 
glioblastomas. Oncogene. 2013;32:3091 –100.  
73. Apurva JA, Kwong NK, Javle M. Genomic Profiling of Biliary Tract Cancers and 
Implications for Clinical Practice Curr Treat Options in Oncol. 2016:17:58.   
74. Hess -Stumpp H. Histone deacetylase inhibito rs and cancer: from cell biology to the clinic. 
Eur J Cell Biol. 2005;84:109 -121.  
75. Abraham J, Nuñez -Álvarez Y, Hettmer S, et al. Lineage of origin in rhabdomyosarcoma 
informs pharmacological response. Genes & Dev. 2014;28:1578 -1591.  
76. Qian, D.Z.; Kachhap, S .K.; Collis, S.J.; Verheul, H.M.; Carducci, M.A.; Atadja, P.; Pi[INVESTIGATOR_45769], R. 
Class II histone deacetylases are associated with VHL -independent regulation of 
hypoxiainducible factor 1 alpha. Cancer Res. 2006;66:8814 –8821.   
77. Schech A, Kazi A, Yu S, Shah P. Histone  Deacetylase Inhibitor Entinostat Inhibits 
TumorInitiating Cells in Triple -Negative Breast Cancer Cells. Mol Cancer Ther. 
2015;14:18481857.  
78. Investigator Brochure: Etinostat, SNDX -27. 2014.  
79. Hodges -Gallagher L, Valentine CD, Bader SE, Kushner PJ. Inhibitio n of histone 
deacetylase enhances the anti -proliferative action of antiestrogens on breast cancer cells and 
blocks tamoxifen -induced proliferation of uterine cells. Breast Cancer Res Treat 
2007;105:297 -309.  
  
  
124  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
80. Acharya MR, Karp JE, Sausville EA et al. Factors  affecting the pharmacokinetic profile of 
MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 
2006;24:367 -375.  
81. Ordentlich P. Pharmacodynamic analysis of ENCORE 301, a placebo -controlled, 
randomized phase 2 study of exe mestane with and without entinostat in postmenopausal 
ER+ breast cancer patients demonstrates an association of lysine hyperacetylation with 
clinical outcome. AACR Molecular Targets Conference 2011  
82. Investigator Brochure: Nivolumab, BMS -936558, MDX1106. 20 14.  
83. Sznol M, Kluger HM, Hodi FS et al. Survival and long -term follow -up of safety and 
response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab 
(anti-PD-1; BMS -936558; ONO -4538). J Clin Oncol 2013;31:ACRA9006.  
84. Brahmer JR, Ho rn L, Antonia SJ et al. Survival and long -term follow -up of the phase I trial 
of nivolumab (Anti -PD-1; BMS -936558; ONO -4538) in patients (pts) with previously 
treated advanced non -small cell lung cancer. J Clin Oncol 2013;31:A8030.  
85. Drake CG, McDermott DF,  Sznol M et al. Survival, safety, and response duration results of 
nivolumab (Anti -PD-1; BMS -936558; ONO -4538) in a phase I trial in patients with 
previously treated metastatic renal cell carcinoma (mRCC): Long -term patient follow -up. J 
Clin Oncol 2013;31: A4514.  
86. Powles, T. et al. MPDL3280A (anti ‑PD‑L1) treatment leads to clinical activity in metastatic 
bladder cancer. Nature. 2014;515:558 –562.  
87. Ansell, S. M. et al. PD ‑1 blockade with nivolumab in relapsed or refractory Hodgkin’s 
lymphoma. N Engl J Med. 201 4;372:311 –319.  
88. Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG -3 and PD -1 
synergistically regulate T -cell function to promote tumoral immune escape. Cancer Res. 
2012;72:917 -927.  
89. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with 
B7h1 expression in human melanocytic lesions supports an adaptive resistance mechanism 
of immune escape. Sci Transl Med. 2012; 4:127ra137.  
90. Ohigashi Y, Sho M, Yamada Y et al.  Clinical significance of programmed death -1 ligand1 
and programmed death -1 ligand -2 expression in human esophageal cancer. Clin Cancer Res. 
2005; 11: 2947 -2953.  
  
  
125  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
91. Wu C, Zhu Y, Jiang J et al. Immunohistochemical localization of programmed death -1 
ligand -1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 
2006;108:19 -24.  
92. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7 -H1 is associated with poor 
prognosis in renal cell carcinoma patients with long -term follow -up. Cancer Res. 
2006 ;66:3381 -3385.  
93. Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the 
programmed death -1 ligand/programmed death -[ADDRESS_376965] in human pancreatic cancer. Clin 
Cancer Res. 2007;13:2151 -2157.  
94. Topalian SL, Hodi FS, Brahmer JR, e t al. Safety, Activity, and Immune Correlates of Anti – 
PD-1 Antibody in Cancer. N Engl J Med.  2012;366:2443 -2454.  
95. Tough DF, Tak PP, Tarakhovsky A, et al. Epi[INVESTIGATOR_308041]: breaking through the 
immune barrier. Nature Reviews Drug Discovery. 2016; 15:835 –853.   
96. Juergens, R. A. et al. Combination epi[INVESTIGATOR_308042] -small cell lung cancer. Cancer Discov. 2011;1:598 –607.  
97. Vanneman M and Dranoff G. Combining Immunotherapy and Targeted Therapi[INVESTIGATOR_308043]. Nat Rev Cancer. 2012;12:237 –251.  
98. Sharma, P. and Allison, J. The future of immune checkpoint therapy. Science 2015;348:56 – 
61.  
99. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new 
immunomodulatory targets. Nat Rev D rug Discov. 2015;14:561 -584.  
100. Marvel D and   Gabrilovich DI. Myeloid -derived suppressor cells in the tumor 
microenvironment: expect the unexpected. J Clin Invest. 2015;125:3356 -3364.  
101. Solito S, Falisi E, Diaz -Montero CM, Doni A, Pi[INVESTIGATOR_308044] L, Rosato A, [LOCATION_009]s cato S, Basso G, 
Zanovello P, Onicescu G, et al. A human promyelocytic -like population is responsible for  
the immune suppression mediated by [CONTACT_308091] -derived suppressor cells. Blood. 
2011;118:2254 –2265.  
102. Markowitz J, Wesolowski,R, Papenfuss T, et al. Myelo id Derived Suppressor Cells in 
Breast Cancer. Breast Cancer Res Treat. 2013;140:13 –21.   
103. Woods DM, Sodré AL, Villagra A, et al. HDAC Inhibition Upregulates PD -1 Ligands in 
Melanoma and Augments Immunotherapy with PD -1 Blockade. Cancer Immunol Res. 
2015;3:1 375-1385.  
  
  
126  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
104. Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the 
programmed death -1 ligand/programmed death -[ADDRESS_376966] in human pancreatic cancer. Clin 
Cancer Res 2007;13:[ADDRESS_376967] cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24:5373 –5380.   
106. Fu J, et al. Increased regulatory T cells correlate with CD8 T -cell impairment and poor 
survival in hepatocell ular carcinoma patients. Gastroenterology. 2007;132:2328 –2339.   
107. Quail DF and Joyce JA. Microenvironmental regulation of tumor progression and 
metastasis. Nat Med. 2013; 19:1423 –1437.  
108. Leoni, F. et al. The antitumor histone deacetylase inhibitor suberoylan ilide hydroxamic acid 
exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci [LOCATION_003]. 
2002;99:2995 –3000.  
109. Yang H, Bueso -Ramos C, DiNardo C, et al. Expression of PD -L1, PD -L2, PD -1 and CTLA4 
in myelodysplastic syndromes is enhance d by [CONTACT_108693]. 
Leukemia. 2014;28:1280 –1288.  
110. Abdelfatah E, Kerner Z, Nanda N, and Nita Ahuja. Epi[INVESTIGATOR_308045]: the right combination. Therap Adv Gastroenterol. 2016;9:560 –579.  
111. Li H, Chiappi[INVESTIGATOR_108639], Guzzetta AA, et al. Immune regulation by [CONTACT_308092] 5 -azacitidine in common human epi[INVESTIGATOR_54578]. Oncotarget. 
2014;5:587 –598  
112. Zitvogel L, Tesniere A, Kroemer G. Cancer despi[INVESTIGATOR_308046]: immunoselection 
and immunosubversion. Nat Rev Immunol 2006;6:715 -727.  
113. Tumeh PC, Harview CL, Yearley JH et al. PD -1 blockade induces responses by [CONTACT_217788]. Nature 2014;515:568 -571.  
114. Llosa NJ, Cruise M, Tam A et al. The vigorous immune microenvironment of microsatellite 
instable colon cancer is balanced by [CONTACT_40900] -inhibitory checkpoints. Cancer Discov 
2015;5:[ADDRESS_376968] cancer patients. Clin Cancer Res 2004;10:[ADDRESS_376969] cancer: Correlative analysis of 
ENCORE 301, a randomized, placebo -controlled phase II trial of exemestane with or 
without entinostat. Oncoimmunology. 2016;5: e1219008.  
117. https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]  
  
  
127  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
118. https://clinicaltrials.gov/ct2/show/NCT0243713 6  
119. Zhu S, Denman CJ, Cobanoglu ZS, et al. The narrow -spectrum HDAC inhibitor entinostat 
enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of 
cancer cells. Pharmaceutical research. 2015;32:779 -792.  
120. Vaccari M, Boasso A, Fen izia C et al. Fatal pancreatitis in simian immunodeficiency virus 
SIV(mac251) -infected macaques treated with 2',3' -dideoxyinosine and stavudine following 
cytotoxic -T-lymphocyte -associated antigen 4 and indoleamine 2,3 -dioxygenase blockade. J 
Virol 2012;86: 108-113  
121. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination 
Immune Checkpoint Blockade. N Engl J Med. [ZIP_CODE];375:1749 -1755.  
122. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, et al. Multicenter phase 
II trial of the histone deacetylase inhibitor pyridylmethyl -N-{4-[(2-
aminophenyl)carbamoyl] -benzyl} -carbamate in pretreated metastatic melanoma. 
Melanoma Res 2008;18:[ADDRESS_376970]. 2000;9:2205 -2216.  
124. Dowlati A, et al. Sequential Tumor Biopsies in Early Phase Clinical Trials of Anticancer 
Agents for Pharmacodynamic Evaluation. Clin Cancer Res 2001; 7: 2971 -76.  
125. Gupta S et al. Quality Improvemen t Guidelines for Percutaneous Needle Biopsy. J Vasc 
Interv Radiol 2010; 21:969 -75  
126. Lee J; Hays JL, Noonan Am,et al. Feasibility and Safety of Sequential Research -Related 
Tumor Core Biopsies in Clinical Trials. Cancer.;119:1357 -64, 2013  
127. Lutz ER, Wu AA, Big elow E, et al. Immunotherapy Converts Nonimmunogenic Pancreatic 
Tumors into Immunogenic Foci of Immune Regulation Cancer Immunol Res. 
2014;2:616632.  
128. Bigelow E, Bever KM, Xu H et al. Immunohistochemical staining of B7 -H1 (PD -L1) on 
paraffin -embedded slides  of pancreatic adenocarcinoma tissue. J Vis Exp 2013(71), e4059, 
doi:10.3791/4059.  
129. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for 
RNA -sequencing and microarray studies. Nucleic Acids Res. 2015:43:e47  
130. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a 
knowledgebased approach for interpreting genome -wide expression profiles. Proc Natl 
Acad Sci U S A. 2005;102:[ZIP_CODE] -50.  
  
  
128  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
131. Mootha VK, Lindgren CM, Eriksson KF et al. PGC -1alpha -responsive genes invol ved in 
oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet.  
2003 Jul;34(3):267 -73.  
  
  
  
  
  
  
     
  
  
129  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
14. APPENDICES   
  
Appendix A: Eastern Cooperative Oncology Group Performance Status Scale, with  
Equivalent Karnofsky Performance Status Scores   
  
 
ECOG1   
Karnofsky2  
Score  Criterion  %  Criterion  
0  Normal activity  100  Normal; no complaints; no evidence of 
disease  
    90  Able to carry on normal activity; minor 
signs or symptoms of disease  
1  Symptoms but ambulatory  80  Normal activity with effort; some signs or 
symptoms of disease  
    70  Cares for self; unable to carry on normal 
activity or do active work  
2  In bed <50% of time  [ADDRESS_376971] of his/her needs  
    50  Requires considerable assistance and 
frequent medical care  
3  In bed >50% of time  40  Disabled, requires special care and 
assistance  
    30  Severely disabled; hospi[INVESTIGATOR_178873]  
4  100% bedridden  20  Very sick; hospi[INVESTIGATOR_98929]  
    10  Moribund; fatal processes progressing 
rapi[INVESTIGATOR_375]  
5  Dead  0  Dead  
1Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the 
Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649 -655.  
2 Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale:  an examination of its reliability and 
validity in a research setting. Cancer. 1984;53:2002 -2007.  
  
  
  
  
  
  
  
130  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
  
  
    
Appendix B:  Patient Drug Information Handout and Wal let Card  
  
Information for Patients, Their Caregivers, and Non -Study Healthcare Team on Possible 
Interactions with Other Drugs and Herbal Supplements   
  
[Note to site:  This appendix consists of an “information sheet” to be handed to the patient at the 
time of enrollment.  Update the “patient name” and study doctor’s/team’s contact [CONTACT_308093].]  
  
The patient, ____________________________, is enrolled on a clinical trial using the 
experimental study drugs:  entinostat and n ivolumab.  This clinical trial is sponsored by [CONTACT_201439].  This form is addressed to the patient, but includes important information 
for others who care for this patient.   
  
These are the things that you as a healthcare provider need to know:  
  
Entinostat and nivolumab are not known or expected to interact with certain enzymes in the body, 
the heart’s electrical activity, or with other medications; however, there is the possi bility of 
interactions.  For instance, entinostat may interact with other drugs that are processed by [CONTACT_6813].    
  
To the patient: Take this paper with you to your medical appointments and keep the 
attached information card in your wallet .    
  
Entinos tat and nivolumab may interact with other drugs which can cause side effects. For this 
reason, it is very important to tell your study doctors of any medicines you are taking before you 
enroll onto this clinical trial.  It is also very important to tell yo ur doctors if you stop taking any 
regular medicines, or if you start taking a new medicine while you take part in this study.  When 
you talk about your current medications with your doctors, include medicine you buy without a 
prescription (over -the-counter  remedy), or any herbal supplements such as St. John’s Wort.  It is 
helpful to bring your medication bottles or an updated medication list with you.  
  
  
  
131  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
Many health care providers can write prescriptions.  You must tell all of your health care providers 
(doctors, physician assistants, nurse practitioners, pharmacists) you are taking part in a clinical 
trial.    
These are the things that you and they need to know:   
  
Before you enroll onto the clinical trial, your study doctor will work with you and your reg ular 
health care providers, as needed, to review any medicines and herbal supplements that you are 
taking or may start during the study.  
  
• Please be very careful!  Over -the-counter drugs (including herbal supplements) may 
contain ingredients that could in teract with your study drug.  Speak to your doctors or 
pharmacist to determine if there could be any side effects.   
• Your regular health care provider should check a frequently updated medical reference or 
call your study doctor before prescribing any new medicine or discontinuing any medicine.  
Your study doctor’s name [CONTACT_832]…_____________________________________   
  
and he or she can be contact[CONTACT_6811] …___________________________________.  
  
  
  
  
  
  
 STUDY DRUG INFORMATION WALLET CARD    
You are enrolled on a clinical trial using the experimental study  drugs 
entinostat and nivolumab . This clinical trial is sponsored by [CONTACT_308094].   
Entinostat and nivolumab may interact with other drugs.   
Because of this, it is very important to:   
➢ Tell yo ur doctors if you stop taking any medicines or if you 
start  taking any new medicines.   
➢ Tell all of your health care providers (doctors, physician 
assistants,  nurse practitioners, or pharmacists) that you are taking part 
in a clinical trial.   
➢ Check with your doctor or pharmacist whenever you need to 
use an  over‐the‐counter medicine or herbal supplement.   
  
  
     Entinostat and nivolumab must be used very carefully with other 
medicines .   
➢ Before you enroll onto the clinical trial, your stud y doctor will work 
with you and your regular health care providers, as needed, to review 
any medicines  and herbal supplements that you are taking or may 
start during the study.   
➢ Before prescribing new medicines, your regular health care 
providers should go to a frequently‐updated medical reference  for 
a list of drugs to avoid, or contact [CONTACT_6814].    
➢ Your study doctor’s name [CONTACT_832] _____________________________  
and can be contact[CONTACT_6811] _________________________________.    
  
  
132  
J1798/Version 5.0/May 21, 2020   
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
 
   
 
  
Appendix D: Management Algorithms for Nivolumab -Related Adverse Events   
  
Adverse Event Management Algorithms:    
GI   
Renal  
Pulmonary  
Hepatic   
Endocrinopathy   
Skin  
Neurological  
  
  
  
  
  
  
    
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
 
 115  
J1798/Version 5.0/May 21, 2020   
 
   
 
  
Appendix E: Concomitant Medications to be Avoided  
Examples of sensitive in vivo  CYP substrates and CYP substrates with narrow therapeutic range 
are summarized in Table 14.1   
  
Table 14.1 Examples of substrates that may be affected by [CONTACT_308095] (e.g., Torsades de Pointes).  
2 Because a number of CYP3A substrates (e.g., darunavir, maraviroc) are also subst rates of P -
gp, the observed increase in exposure could be due to inhibition of both CYP3A and P -gp.  
[ADDRESS_376972] John’s Wort, tipranavir/ritonavir  
  
Phase 2 Study Of Entinostat and Nivolumab in Unresectable or Metastatic Cholangiocarcinoma   
and Pancreatic Adenocarcinoma   
Principal Investigator:  [INVESTIGATOR_307987], M.D.    
  
   
CYP Enzymes  Substrates with narrow therapeutic range  1   
CYP1A2  Theophylline, tizanidine  
CYP2C8  Paclitaxel  
CYP3A  2   Alfentanil,  astemizole  3 ,  cisapride  4 cyclosporine,  ,  
ihydroergotamine, ergotamine, fentanyl, pi[INVESTIGATOR_3924], quinidine,  
sirolimus, tacrolimus, terfenadine  4   
1   CYP substrates with narrow therapeutic range refers to drugs whose exposure -response  
 
   
    
123  
J1798/Version 5.0/May 21, 2020   